PBS Latest News

2026

June 2026

Redesigned PBS website improves search functionality and medicine visibility - 18 June 2026

PBAC Update May 2026 - 11 June 2026

PBS Website Update - 1 June 2026

May 2026

Changes to PBS Wholesale Mark-up (WMU) fees from 1 July - 29 May 2026

Consultation open for National Pharmacy Workforce Analysis - 14 May 2026

Delisting of goserelin 3.6 mg implant (Zoladex Implant™) from the Pharmaceutical Benefits Scheme - 1 November 2026 - 13 May 2026

Update to Agenda for the July 2026 PBAC Meeting - 8 May 2026

PBAC Update April 2026 - 7 May 2026

Update to Agenda for the May 2026 PBAC Meeting - 1 May 2026

Amendment to the schedule description of an item on the Pharmaceutical Benefits Schedule - 1 May 2026

PBS Website Update - 1 May 2026

April 2026

Public Consultation: Draft 2026-27 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 30 April 2026

Have your say on the framework for consumer engagement in HTA - 29 April 2026

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – March 2026 - 24 April 2026

PBAC Public Summary Documents – December 2025 meeting - 24 April 2026

Publication: 24-month Review of the Minimum Stockholding Requirements - 24 April 2026

Updates and Resources for Remote Area Aboriginal Health Services (RAAHS) Prescriptions - 22 April 2026

Outcome Statement for February 2026 Stakeholder Sponsor Meeting: Multiple Myeloma - 17 April 2026

PBS listing of lamotrigine for bipolar disorder - 8 April 2026

PBAC Update March 2026 - 7 April 2026

PBS listing update for macrogol 3350, sachets containing powder for oral solution 13.125 g with electrolytes, 30, oral, effective - 1 April 2026

PBS restriction changes for antihypertensive dual therapy fixed dose combinations - 1 April 2026

PBS Website Update - 1 April 2026

March 2026

Agenda for the July 2026 PBAC meeting – 25 March 2026

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – November 2025 meeting - 20 March 2026

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 20 March 2026

PBAC advice on equitable access to GLP-1 obesity treatments - 17 March 2026

Public consultation open for revised Code of Ethics for Pharmacists - 11 March 2026

PBAC Public Summary Documents – November 2025 meeting - 6 March 2026

Changes to PBS indications for nivolumab and ipilimumab - 1 March 2026

PBS Website Update - 1 March 2026

February 2026

Update to Agenda for the March 2026 PBAC Meeting - 9 February 2026

PBS Website Update - 1 February 2026

January 2026

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – December 2025 Intracycle Meeting - 30 January 2026

Update to Agenda for the March 2026 PBAC Meeting - 9 January

PBS Website Update - 1 January 2026

2025

December 2025

PBAC Public Summary Documents – September 2025 meeting - 24 December 2025

PBS Expenditure and Prescriptions Report 2024-25 - 22 December 2025

PBS subsidy arrangements for clonidine tablets SSSI - 22 December 2025

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – November 2025 - 19 December 2025

PBAC Update December 2025 - 18 December 2025

PBAC Update for the November 2025 PBAC Meeting - 12 December 2025

PBS XML and Text files – discontinued from May 2026 - 11 December 2025

Closing 15 December 2025: Seeking expressions of interest — Health Technology Assessment advisory committees members - 10 December 2025

Update to Continued Dispensing Arrangements – Emergency Measure - 10 December 2025

ACSS payments to approved pharmacists - 8 December 2025

Agenda for the December 2025 PBAC Meeting - 5 December 2025

PBS subsidy arrangements for simvastatin tablets SSSI - 5 December 2025

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 3 December 2025

Medication Program for Homeless People - 1 December 2025

PBS Website Update - 1 December 2025

November 2025

PBS subsidy arrangements for nicorandil tablets SSSI - 28 November 2025

Sponsor Information Session - 27 November 2025

Agenda for the March 2026 PBAC meeting – 19 November 2025

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – July 2025 meeting - 14 November 2025

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 14 November 2025

Post-market Review workplan (September 2025) published - 13 November 2025

Error in the current PBS listings for brentuximab vedotin for Stage III or IV CD30 positive Hodgkin lymphoma, listed on 1 November 2025 - 11 November 2025

PBS Website Update - 1 November 2025

October 2025

PBAC Public Summary Documents – July 2025 meeting - 31 October 2025

Seeking expressions of interest — Health Technology Assessment advisory committees members - 24 October 2025

Review of PBS Prescriber Bag Schedule Tranche 1 – September 2025 PBAC recommendations - 23 October 2025

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – September 2025 Intracycle Meeting - 17 October 2025

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 10 October 2025

1 October 2025 designated brand list – minimum stockholding requirements - 1 October 2025

PBS Website Update - 1 October 2025

September 2025

Outcome Statement for August 2025 Stakeholder Meeting: Pulmonary Arterial Hypertension - 23 September 2025

Further information about the Department’s request for earlier Notices of Intent for submissions to the PBAC - 18 September 2025

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – May 2025 meeting - 12 September 2025

Outcome Statement for July 2025 Stakeholder Meeting: Multiple Myeloma - 11 September 2025

Consultation open for review of Code of Ethics for Pharmacists - 9 September 2025

Public consultation open on equitable access to medicines for the treatment of obesity - 5 September 2025

Changes to the Notice of Intent process for submissions to the PBAC - 5 September 2025

Update to Agenda for the September 2025 PBAC Meeting - 2 September 2025

PBS Website Update - 1 September 2025

August 2025

PBAC Public Summary Documents – May 2025 meeting - 29 August 2025

Agenda for the September 2025 PBAC Intracycle Meeting - 29 August 2025

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – July 2025 - 22 August 2025

Department published revised Pharmaceutical Benefits Scheme Minimum Stockholding Guidelines - 14 August 2025

Advice regarding Xolair (omalizumab) Claiming - 8 August 2025

PBAC Update for the July 2025 PBAC Meeting - 4 August 2025

PBS Website Update - 1 August 2025

July 2025

Agenda for the November 2025 PBAC meeting – 30 July 2025

Review of clinical guidelines and cost estimates for the use of anti-epileptic drugs (AEDs) for the treatment of epilepsy - 25 July 2025

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – March 2025 meeting - 18 July 2025

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 18 July 2025

PBAC Public Summary Documents – March 2025 meeting - 4 July 2025

Error in the current PBS listings for abemaciclib for Early breast cancer - 1 July 2025

PBS Website Update - 1 July 2025

June 2025

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – May 2025 Intracycle Meeting - 20 June 2025

ACSS payments to approved pharmacists to be automated from 1 July 2025 - 17 June 2025

Update to Agenda for the May 2025 PBAC Meeting - 4 June 2025

PBS Website Update - 1 June 2025

May 2025

Update to Continued Dispensing Arrangements – Emergency Measure - 23 May 2025

PBAC Update for the May 2025 PBAC Meeting - 23 May 2025

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 16 May 2025

Update to Agenda for the July 2025 PBAC Meeting - 9 May 2025

Update to Agenda for the May 2025 PBAC Meeting - 2 May 2025

PBS Website Update - 1 May 2025

April 2025

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – March 2025 - 24 April 2025

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – December 2024 meeting - 24 April 2025

Pharmaceutical Benefits Scheme (PBS) Safety Net Threshold changes - 17 April 2025

PBAC Update for the March 2025 PBAC Meeting - 14 April 2025

PBAC Public Summary Documents – December 2024 meeting - 11 April 2025

New Minimum Stockholding Requirements Online Notification Portal and Fact Sheet - 9 April 2025

Agenda for the July 2025 PBAC meeting - 2 April 2025

Expanded access to empagliflozin for type 2 diabetes patients with high cardiovascular risk - 1 April 2025

Shortages of hormone replace therapy (HRT) patches: PBS subsidy and substitution of Estradot, Estraderm MX and overseas alternatives - 1 April 2025

1 April 2025 designated brand list – minimum stockholding requirements - 1 April 2025

PBS Website Update - 1 April 2025

March 2025

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 21 March 2025

PBAC Public Summary Documents (first time decisions not to recommend and deferrals)– November 2024 meeting - 21 March 2025

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 14 March 2025

New Minimum Stockholding Requirement Fact Sheets and Updated Web Content - 12 March 2025

PBAC Public Summary Documents – November 2024 meeting - 7 March 2025

Update to Continued Dispensing Arrangements – Emergency Measures - 5 March 2025

Shortages of hormone replace therapy (HRT) patches: PBS subsidy and substitution of Estradot, Estraderm MX and overseas alternatives - 4 March 2025

PBS item supply for formerly private prescription items (e.g. Yaz® and Yasmin® – listed from 1 March) - 1 March 2025

PBS Website Update - 1 March 2025

February 2025

Update to Continued Dispensing Arrangements – Emergency Measures - 5 February 2025

Changes to PBS listings for endorsed midwife prescribing – 1 February 2025

PBS Website Update - 1 February 2025

January 2025

Outcomes of the December 2024 PBAC Intracycle meeting - 31 January 2025

Public Consultation: Draft 2025-26 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 31 January 2025

PBS reason codes 162/163 when dispensing biosimilar brands - 23 January 2025

PBS Website Update - 1 January 2025

2024

December 2024

PBAC Public Summary Documents – September 2024 meeting - 24 December 2024

PBAC Update December 2024 - 23 December 2024

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – November 2024 - 20 December 2024

Shortages of hormone replace therapy (HRT) patches: PBS subsidy and substitution of Estradot, Estraderm MX and overseas alternatives - 20 December 2024

Utilisation analysis of heart failure medicines listed on the Pharmaceutical Benefits Scheme (PBS) - 20 December 2024

PBS Expenditure and Prescriptions Report 2023-24 - 19 December 2024

Report on PBS/RPBS Under Co-payment Prescriptions Data 2023-24 - 19 December 2024

Agenda for the May 2025 PBAC Meeting - 18 December 2024

PBS subsidy arrangements for insulin isophane injection SSSI - 18 December 2024

Outcome Statements for October 2024 Stakeholder Meetings: Oral Contraceptives and Migraine - 9 December 2024

Agenda for the December 2024 PBAC Intracycle meeting - 6 December 2024

2023-24 financial results for cost recovery activities for listing medicines on the PBS and designated vaccines on the NIP - 4 December 2024

Error in the PBS listings for methylphenidate hydrochloride modified release tablet (Concerta, Methylphenidate-TEVA XR, Methylphenidate XR ARX) - 4 December 2024

HTA Policy and Methods Review update - 3 December 2024

Pharmaceutical Benefits Scheme (PBS) | Changes to PBS listings for Opdualag® and Vyxeos® - 1 December 2024

New PBS Schedule Data API and API CSV files - 1 December 2024

PBAC Recommendations for amendments to COVID-19 oral treatment restrictions - 1 December 2024

Expanded access to dapagliflozin for type 2 diabetes patients with high cardiovascular risk - 1 December 2024

PBS Website Update - 1 December 2024

November 2024

Agenda for the March 2025 PBAC meeting – 28 November 2024

Update on the March 2025 meeting – 28 November 2024

PBAC Update November 2024 – 28 November 2024

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 22 November 2024

PBS subsidy arrangements for estradiol transdermal patches SSSI - 19 November 2024

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 15 November 2024

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) - July 2024 meeting - 15 November 2024

PBAC Public Summary Documents – July 2024 meeting - 1 November 2024

Changes to PBS listings for nurse practitioner prescribing - 1 November 2024

PBS Website Update - 1 November 2024

October 2024

Pharmaceutical Benefits Advisory Committee process for managing its March 2025 agenda - 30 October 2024

Submissions to the March 2025 meeting of the Pharmaceutical Benefits Advisory Committee - 24 October 2024

Post-market Review workplan (September 2024) published - 21 October 2024

Outcomes of the September 2024 PBAC Intracycle meeting - 18 October 2024

Pharmaceutical Benefits Scheme – Clarity on Price Disclosure Reduction Thresholds and Designated Brands - 1 October 2024

1 October 2024 designated brand list – minimum stockholding requirements - 1 October 2024

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) - May 2024 - 1 October 2024

Error in Brand Price Premiums for Sevikar 20/5 and Sevikar 40/10 in the 1 October 2024 Schedule - 1 October 2024

PBS Website Update - 1 October 2024

September 2024

PBS arrangements due to shortage of tenofovir with emtricitabine tablets - 23 September 2024

Final reports of the HTA Policy and Methods Review and Enhanced Consumer Engagement Process - 10 September 2024

Updated Agenda for the November 2024 PBAC meeting – 6 September 2024

Error in new migalastat PBS listing - 1 September 2024

Error in new 60 day dispensing listings for complex gastro-oesophageal reflux disease and asthma - 1 September 2024

Substitution of GABAPENTIN-WGR - 1 September 2024

PBS Website Update - 1 September 2024

August 2024

PBAC Public Summary Documents – May 2024 meeting - 30 August 2024

Agenda for the September 2024 PBAC Intracycle meeting - 30 August 2024

Publication of 12-month review of Minimum Stockholding Requirements and Excel breach notification form - 28 August 2024

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – July 2024 - 23 August 2024

PBAC Update August 2024 - 19 August 2024

New PBS listing for migalastat (Galafold®) for the treatment of Fabry disease - 19 August 2024

Xolair® (omalizumab) PBS pricing information - 1 August 2024

Advance notice of 1 February 2025 change in Authority level for saxagliptin with dapagliflozin (Qtern® 5/10) - 1 August 2024

PBS Website Update - 1 August 2024

July 2024

Agenda for the November 2024 PBAC meeting – 31 July 2024

PBAC Public Summary Documents – March 2024 meeting (first time decisions not to recommend and deferrals) - 19 July 2024

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 19 July 2024

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 19 July 2024

Updates to the HTA Policy and Methods Review - 10 July 2024

Post-market Review workplan (May 2024) published - 8 July 2024

PBAC Public Summary Documents – March 2024 meeting - 5 July 2024

Expansion of the CTG PBS Co-Payment Program - 1 July 2024

Update - 13485R - CALCIUM, calcium carbonate 1.25 g (calcium 500 mg) chewable tablet, 120 (Cal-500) – Prescriber code permissions - 1 July 2024

PBS Website Update - 1 July 2024

June 2024

2024-25 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 28 June 2020

PBAC Update June 2024 - 25 June 2024

Outcomes of the May 2024 PBAC Intracycle meeting - 21 June 2024

Update - Substitution for new brand of Budesonide + Formoterol listings - 13 June 2024

1 June 2024 updates as part of the Digital Transformation of Authority Required (Written) PBS listings - 1 June 2024

PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines - 1 June 2024

PBS Website Update - 1 June 2024

May 2024

Historical Archive of PBS Schedules from 1951 to 2002 - 23 May 2024

Drug Utilisation Sub-Committee (DUSC) utilisation analysis of medicines for type 2 diabetes - 21 May 2024

PBS subsidy arrangements for abatacept 125 mg SSSI - 15 May 2024

Updated Agenda for the July 2024 PBAC meeting – 10 May 2024

Agenda for the May 2024 PBAC Intracycle meeting - 3 May 2024

PBS Website Update - 1 May 2024

April 2024

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – March 2024 - 26 April 2024

Publication of Stage 1 and Stage 2 PBS Process Improvements metrics report for 2022-23 - 19 April 2024

Updates to the HTA Policy and Methods Review Reference Committee – 15 April 2024

PBAC Public Summary Documents – December 2023 meeting - 5 April 2024

Agenda for the July 2024 PBAC meeting – 3 April 2024

National Health (Pharmaceutical Benefits) Regulations 2017 amendments - 3 April 2024

Public Consultation: Draft 2024-25 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 2 April 2024

1 April 2024 designated brand list – minimum stockholding requirements - 1 April 2024

PBS Website Update - 1 April 2024

March 2024

Stocktake of PBS medicines available for endometriosis and related conditions Report - 28 March 2024

Updates to the HTA Policy and Methods Review Reference Committee – 26 March 2024

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 22 March 2023

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 22 March 2024

PBAC Chair and MSAC Chair and Deputy Chairs EOI outcome - 22 March 2024

Consultation Open: Co-design of an Enhanced Consumer Engagement Process - 18 March 2024

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – November 2023 meeting - 15 March 2024

Updates to the HTA Policy and Methods Review Reference Committee – 8 March 2024

Updated Agenda for March 2024 PBAC Meeting – 6 March 2024

Pharmaceutical Reform Agreement (PRA) Review Report - 6 March 2024

PBAC Public Summary Documents – November 2023 meeting - 1 March 2024

PBS arrangements due to discontinuation of Ordine 10 (morphine hydrochloride trihydrate) oral liquids effective 1 March 2024 - 1 March 2024

Nurse practitioner and endorsed midwife prescribing: consultation survey live - 1 March 2024

PBS Website Update - 1 March 2024

February 2024

PBS subsidy arrangements for gliclazide 30 mg tablets SSSI - 29 February 2024

Updates to the HTA Policy and Methods Review Reference Committee – 21 February 2024

Updates to the HTA Review Research and analysis papers collection: Emerging Health Technologies - 15 February 2024

Updates to the HTA Policy and Methods Review Reference Committee – 13 February 2024

Updates to the HTA Review: Consultation 2 Survey live - 6 February 2024

PBS arrangements due to shortage of Zactin Tablet® (fluoxetine) dispersible tablets effective 1 February 2024 - 2 February 2024

Updates to the HTA Policy and Methods Review Reference Committee – 1 February 2024

PBS subsidy arrangements for fluoxetine 10 mg capsules SSSI - 1 February 2024

PBS Website Update - 1 February 2024

January 2024

2024 PBS Post-market Review Framework - 31 January 2024

Outcomes of the December 2023 PBAC Intracycle meeting - 25 January 2024

Updates to the HTA Review: Options paper for Consultation 2 published - 25 January 2024

Updates to the HTA Policy and Methods Review Reference Committee – 18 January 2024

PBAC Public Summary Documents (first time decisions not to recommend and deferrals)– September 2023 meeting - 12 January 2024

Updates to the HTA Policy and Methods Review Reference Committee – 05 January 2024

Updates to the HTA Review Research and Analysis papers collection: Draft HTA expert papers published - 4 January 2024

PBS Website Update - 1 January 2024

2023

December 2023

PBS Expenditure and Prescriptions Report 2022-23 - 22 December 2023

PBAC Public Summary Documents – September 2023 meeting - 22 December 2023

Update to Continued Dispensing Arrangements – Emergency Measures - 22 December 2023

Report on the Collection of Under Co-payment Data 2022-23 - 15 December 2023

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – November 2023 - 15 December 2023

PBS subsidy arrangements for fluoxetine SSSI - 11 December 2023

PBS reason codes 162/163 when dispensing biosimilar brands - 8 December 2023

Updates to the HTA Policy and Methods Review Reference Committee – 8 December 2023

Agenda for the December 2023 PBAC Intracycle meeting - 1 December 2023

Updates to the HTA Policy and Methods Review Reference Committee – 1 December 2023

PBS Website Update - 1 December 2023

PBS Safety Net early supply for 60-day prescriptions - 1 December 2023

PBS arrangements due to discontinuation of the Ordine brands of morphine hydrochloride trihydrate oral liquids effective 1 December 2023 - 1 December 2023

1 December 2023 Changes to the PBS Listings of Medicines for the Treatment of Ankylosing Spondylitis - 1 December 2023

November 2023

Agenda for the March 2024 PBAC meeting – 22 November 2023

Updates to the HTA Review Research and Analysis papers collection: Draft HTA expert paper published - 22 November 2023

Updates to the HTA Policy and Methods Review Reference Committee – 16 November 2023

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 14 November 2023

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 13 November 2023

PBAC Public Summary Documents – July 2023 meeting - 10 November 2023

Updates to the HTA Review: Consultation 1 report published - 10 November 2023

Updates to the HTA Policy and Methods Review Reference Committee – 9 November 2023

Updates to the HTA Policy and Methods Review Reference Committee – 3 November 2023

PBS arrangements during shortage of amoxicillin and clavulanate potassium 400 mg/57 mg per 5 mL oral suspension effective 1 November 2023 - 1 November 2023

PBS Website Update - 1 November 2023

October 2023

Updates to the HTA Review Research and analysis papers collection: Draft HTA expert paper published - 30 October 2023

Updated Agenda for November 2023 PBAC Meeting – 30 October 2023

Expressions of Interest to join the Pharmaceutical Benefits Remuneration Tribunal - 30 October 2023

PBAC Public Summary Documents – July 2023 meeting - 27 October 2023

Updates to the HTA Review Research and analysis papers collection: Draft HTA expert papers published - 25 October 2023

Updates to the HTA Policy and Methods Review Reference Committee – 23 October 2023

1 November 2023 Changes to the PBS Listings of Medicines for Severe Active Rheumatoid Arthritis - 23 October 2023

1 November 2023 changes to the PBS listings of medicines for children and adolescents with Chronic Plaque Psoriasis - 23 October 2023

Outcomes of the September 2023 PBAC Intracycle meeting - 13 October 2023

Updates to the HTA Policy and Methods Review Reference Committee – October 2023 - 11 October 2023

Updates to the HTA Policy and Methods Review Reference Committee – 11 October 2023

1 October 2023 designated brand list – minimum stockholding requirements - 1 October 2023

PBS Website Update - 1 October 2023

September 2023

2023 October Price Disclosure Cycle – Patient savings - 29 September 2023

Updated Agenda for November 2023 PBAC Meeting – 25 September 2023 - 27 September 2023

Updates to the HTA Policy and Methods Review Reference Committee – 26 September 2023

Updates to the Health Technology Assessment Policy and Methods Review Reference Committee – 22 September 2023

International HTA collaboration expands - 20 September 2023

PBS subsidy arrangements for vigabatrin SSSI - 15 September 2023

Updates to the Health Technology Assessment Policy and Methods Review Reference Committee - 15 September 2023

Updated Agenda for November 2023 PBAC Meeting – 14 September 2023

Updates to the Health Technology Assessment Policy and Methods Review Reference Committee – September 2023 - 8 September 2023

Review of cancer related surrogate outcomes used for Pharmaceutical Benefits Advisory Committee (PBAC) decision making - 8 September 2023

Updated Agenda for November 2023 PBAC Meeting – 1 September 2023

Information regarding brands of colestyramine and changes to PBS listing of s19A JAMP CHOLESTYRAMINE effective 1 September 2023 - 1 September 2023

Extended closing date - Seeking expressions of interest - health technology assessment advisory committee - 1 September 2023

Updated Agenda for the September 2023 PBAC meeting – 31 August 2023 - 1 September 2023

PBS Website Update - 1 September 2023

August 2023

Updates to the Health Technology Assessment Policy and Methods Review Reference Committee - 30 August 2023

Efficient Funding of Chemotherapy (EFC) Review – Final Report - 28 August 2023

Agenda for the September 2023 PBAC Intracycle meeting - 25 August 2023

PBAC Public Summary Documents – May 2023 meeting - 25 August 2023

Updates to the Health Technology Assessment Policy and Methods Review (HTA Review) including Consultation 1 Responses Published - 23 August 2023

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – July 2023 - 18 August 2023

Estimating overall survival in people receiving Pharmaceutical Benefits Scheme (PBS)-listed cancer medicines in Australian clinical practice - 18 August 2023

Update from the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023 - 15 August 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023 - 14 August 2023

Seeking expressions of interest — health technology assessment advisory committees - 11 August 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – July 2023 - 2 August 2023

International Harmonisation of Ingredient Names (IHIN) - changes to the PBS Schedule effective - 1 August 2023

PBS subsidy arrangements for cefalexin SSSI - 1 August 2023

PBS Website Update - 1 August 2023

July 2023

Update - Substitution of Budesonide + Formoterol listings - 28 July 2023

Agenda for the November 2023 PBAC meeting - 26 July 2023

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 20 July 2023

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 18 July 2023

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – March 2023 meeting - 14 July 2023

Recommendations made out-of-session by the PBAC March 2023 and July 2023 meetings – Update to outcome for MS-2 Step® - 14 July 2023

Substitution of Budesonide + Formoterol listings - 14 July 2023

Recommendations made out-of-session by the PBAC March 2023 and July 2023 meetings – Changes to MS-2 Step® PBS Listing - 11 July 2023

PBS Subsidy arrangements for insulin degludec and insulin aspart - 6 July 2023

Changes to PBS listing of methadone oral liquid, effective date 1 July 2023 - 1 July 2023

1 July 2023 updates as part of the Digital Transformation of Authority Required (Written) PBS listings - 1 July 2023

PBS Website Update - 1 July 2023

June 2023

PBAC Public Summary Documents – March 2023 meeting - 30 June 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 30 June 2023

Connecting to the national Prescription Delivery Service - 30 June 2023

2023-24 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 28 June 2023

ODT Factsheet update - 28 June 2023

Changes to Paxlovid® PBS eligibility criteria - 23 June 2023

Factsheets for the opioid dependence treatment 1 July 2023 changes - 19 June 2023

Outcomes of the May 2023 PBAC Intracycle meeting - 16 July 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 9 June 2023

PBS Website Update - 1 June 2023

May 2023

Health Technology Assessment Policy and Methods Review Consultation and Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 26 May 2023

PBAC Public Summary Documents - 24 May 2023

Outcome in relation to fluticasone propionate – PBAC May 2023 Intracycle meeting - 12 May 2023

Public Consultation: Draft 2023-24 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 12 May 2023

May 2023 Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 11 May 2023

Reforming Opioid Dependence Treatment Access - 10 May 2023

Recommendations made out-of-session by the PBAC between March 2023 and July 2023 meetings - 10 May 2023

Publication of Notification Form for likely or actual breach of minimum stockholding requirements - 8 May 2023

Updated Agenda for the July 2023 PBAC meeting - 5 May 2023

PBS subsidy arrangements for cefaclor SSSI - 2 May 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 1 May 2023

PBS Website Update - 1 May 2023

April 2023

Agenda for the May 2023 PBAC Intracycle meeting - 28 April 2023

Changes to treatment phases and authority levels in medicines for the treatment of Alzheimer’s disease - 24 April 2023

Recommendations made by the PBAC – March 2023 - 21 April 2023

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – December 2022 meeting - 21 April 2023

Publication of Stage 1 and Stage 2 PBS Process Improvements metrics report for 2021-22 - 21 April 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – March and April 2023 - 20 April 2023

PBS subsidy arrangements for phenoxymethylpenicillin SSSI - 18 April 2023

Health Technology Assessment (HTA) Policy and Methods Review Consultation - 11 April 2023

PBAC Public Summary Documents – December 2022 meeting - 6 April 2023

Flutiform 50/5® (fluticasone propionate + formoterol (eformoterol)) PBS pricing information - 3 April 2023

Novorapid® (insulin aspart) PBS pricing information - 1 April 2023

Revised PBS restrictions for fluticasone propionate 50 micrograms per dose inhalers - 1 April 2023

PBS Website Update - 1 April 2023

March 2023

Update to the Image-based prescribing Special Arrangement - 31 March 2023

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 31 March 2023

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 31 March 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 31 March 2023

2023 April Price Disclosure Cycle – Patient savings - 31 March 2023

Agenda for the July 2023 PBAC meeting - 29 March 2023

Terms of Reference for the Health Technology Assessment Policy and Methods Review - 22 March 2023

PBS subsidy arrangements for warfarin SSSI - 17 March 2023

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) - 17 March 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – March 2023 - 9 March 2023

PBAC Public Summary Documents – November 2022 meeting - 3 March 2023

PBS Website Update - 1 March 2023

February 2023

Recommendations made out-of-session by the PBAC November 2022 and March 2023 meetings - 24 February 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – February 2023 - 10 February 2023

Improved Access to PBS medicines for Pulmonary Arterial Hypertension (PAH) - 3 February 2023

PBS Website Update - 1 February 2023

Changes to PBS listing of morphine and oxycodone oral solutions, effective date 1 Feb 2023 - 1 February 2023

January 2023

Outcomes of the December 2022 PBAC Intracycle meeting - 27 January 2023

Updates from the Health Technology Assessment Policy and Methods Review Reference Committee - 20 January 2023

Consultation on the revised PBS Post-market Review (PMR) Framework – Publication of responses - 20 January 2023

PBAC Public Summary Documents – September 2022 meeting - 13 January 2023

Recommendations made out-of-session by the PBAC between July 2022 and November 2022 meetings - 6 January 2023

Updated Agenda for the March 2023 PBAC meeting - 4 January 2023

PBS Website Update - 1 January 2023

2022

December 2022

PBAC Public Summary Documents – September 2022 meeting - 23 December 2022

Final report for the Post-market Review of medicines for smoking cessation and Review outcomes - 22 December 2022

PBS Expenditure and Prescriptions Report 2021-22 - 21 December 2022

PBS subsidy arrangements for cefalexin SSSI - 21 December 2022

Refreshed National Medicines Policy - 20 December 2022

Recommendations made by the PBAC – November 2022 - 16 December 2022

Report on the Collection of Under Co-payment Data 2021–22 - 14 December 2022

PBS subsidy arrangements for amoxicillin SSSI - 6 December 2022

Agenda for the December 2022 PBAC Intracycle meeting - 2 December 2022

PBS Website Update - 1 December 2022

November 2022

External consultation on the draft revised Post-market Review Framework – Deadline extension - 29 November 2022

Outcome in relation to discussion of COVID-19 oral treatments – PBAC November 2022 - 24 November 2022

Agenda for the March 2023 PBAC meeting - 23 November 2022

PBAC Public Summary Document - 18 November 2022

PBAC Public Summary Documents – September 2022 meeting - 11 November 2022

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 Meeting - 11 November 2022

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 3 November 2022

Expanded access to COVID-19 oral antiviral treatments on the PBS - 1 November 2022

Removal of the temporary PBS listings introduced during the tocilizumab shortage, which allowed patients to transition off tocilizumab and onto another biological disease modifying drug - 1 November 2022

1 November 2022 updates as part of the Digital Transformation of Authority Required (Written) PBS listings - 1 November 2022

PBS Website Update - 1 November 2022

October 2022

PBAC Public Summary Documents – July 2022 meeting - 28 October 2022

Reference Committee for the Health Technology Assessment Policy and Methods Review - 27 October 2022

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 25 October 2022

PBS Minimum Stockholding Requirements - 21 October 2022

Consultation on the revised PBS Post-market Review (PMR) Framework - 20 October 2022

Outcomes of the September 2022 PBAC Intracycle meeting - 14 October 2022

2022 October Price Disclosure Cycle – Confirmed prices and patient savings reports - 1 October 2022

PBS Website Update - 1 October 2022

September 2022

2022 October Price Disclosure Cycle – Confirmed prices and patient savings reports - 19 September 2022

PBAC Public Summary Documents (first time rejections and deferrals) - May 2022 meeting - 9 September 2022

Efficient Funding of Chemotherapy (EFC) Review - Interim Report - 5 September 2022

Collaboration Arrangement between the Department of Health and Aged Care and Health Technology Assessment bodies in the United Kingdom and Canada - 5 September 2022

Updated Agenda for the November 2022 PBAC meeting - 2 September 2022

PBS Website Update - 1 September 2022

August 2022

Agenda for the September 2022 PBAC Intracycle meeting - 26 August 2022

PBAC Public Summary Documents – May 2022 meeting - 26 August 2022

Health Products Portal has a new website - 23 August 2022

Update – National Medicines Policy Review – Registrations for Targeted Stakeholder Consultation Sessions and Open Public Forum are now open - 22 August 2022

Recommendations made by the PBAC - July 2022 - 19 August 2022

1 September 2022 updates as part of the Digital Transformation of Authority Required (Written) PBS listings - 19 August 2022

Restart of the National Medicines Policy Review – Further Consultation on a Revised Draft of the National Medicines Policy - 17 August 2022

2022-2023 Cost Recovery Implementation Statement (CRIS)- 12 August 2022

Ezetimibe (Ezetrol) PBS claiming issue – August 2022 - 5 August 2022

Changes to cost recovery arrangements from 1 August 2022 - 1 August 2022

Changes to PBS listing of hydromorphone oral solution - 1 August 2022

PBS Website Update - 1 August 2022

July 2022

2022 October Price Disclosure Cycle – Patient savings -  29 July 2022

Agenda for the November 2022 PBAC meeting -  27 July 2022

PBAC Public Summary Documents (first time rejections and deferrals) – March 2022 meeting - 15 July 2022

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 11 July 2022

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 11 July 2022

Expanded eligibility criteria for COVID-19 oral antiviral treatments, Paxlovid® (nirmatrelvir and ritonavir) and molnupiravir (Lagevrio®) - 10 July 2022

PBAC Recommendation for amendments to COVID-19 oral treatment restrictions - 10 July 2022

2022 October Price Disclosure Cycle – Indicative Prices - 4 July 2022

PBAC Public Summary Documents – March 2022 meeting - 1 July 2022

New Strategic Agreements with the Medicines Industry – PBS Website Updates - 1 July 2022

Update to Continued Dispensing Arrangements - 1 July 2022

PBS Website Update - 1 July 2022

June 2022

Digital Transformation of Authority Required (Written) PBS listings - 30 June 2022

Electronic National Residential Medication Charts (eNRMC) National Rollout - 27 June 2022

Price Disclosure 2022 October Cycle Outcomes Summary - 24 June 2022

Outcomes of the May 2022 PBAC Intracycle meeting - 17 June 2022

Public Consultation: Draft 2022-23 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 17 June 2022

Pharmaceutical Benefits Scheme Safety Net threshold reduction from 1 July 2022 - 16 June 2022

Updated Price Disclosure Guidelines, Price Disclosure webpages and Price Disclosure Dispute Resolution Process - 8 June 2022

PBS Website Update - 1 June 2022

May 2022

Remake of National Health (Supply of Pharmaceutical Benefits – Under Co-payment Data and Claims for Payment) Rules 2022 - 25 May 2022

Review of discount rate in the PBAC guidelines - 25 May 2022

Remake of the National Health (Pharmaceuticals and Vaccines – Cost Recovery) Regulations 2009 - 11 May 2022

Updated Agenda for the July 2022 PBAC Meeting - 6 May 2022

PBS Website Update - 1 May 2022

April 2022

Agenda Update for the May 2022 PBAC Intracycle meeting - 29 April 2022

Recommendations made by the PBAC - March 2022 - 22 April 2022

PBAC Public Summary Documents (first time decisions not to recommend, deferrals and other matters) – December 2021 meeting - 14 April 2022

Reference Committee for the Health Technology Assessment Policy and Methods Review - 10 April 2022

Paxlovid® (nirmatrelvir and ritonavir) PBS listing - 9 April 2022

PBAC Recommendation for nirmatrelvir and ritonavir (Paxlovid®) March 2022 - 9 April 2022

Clarity about Supply Only arrangements - 5 April 2022

Consultation now open - review of base case discount rate at 3A.1 of the PBAC guidelines - 5 April 2022

Publication of updated Ministerial Discretion Guidance Material for Statutory Price Reductions (SPR) - 1 April 2022

PBAC Public Summary Documents – December 2021 meeting - 1 April 2020

PBS Website Update - 1 April 2022

March 2022

2022 April Cycle - Brand Price Reductions and Savings to Patients - 31 March 2022

Agenda for the July 2022 PBAC meeting - 30 March 2022

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 24 March 2022

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 24 March 2022

PBAC Public Summary Documents – November 2021 meeting (first time rejections and deferrals) - 18 March 2022

1 April 2022 Price Disclosure Confirmed Prices - 15 March 2022

PBAC Public Summary Documents – November 2021 meeting - 4 March 2022

Lagevrio® (molnupiravir) PBS listing - 1 March 2022

PBS Website Update - 1 March 2022

February 2022

PBAC Recommendation for molnupiravir (Lagevrio®) - 25 February 2022

PBS Arrangements for medicines for the treatment of paroxysmal nocturnal haemoglobinuria - 21 February 2022

Agenda for the May 2022 PBAC Intracycle meeting - 11 February 2022

Review of the National Medicines Policy – Consultation on Draft National Medicines Policy Extended – Closes 2 March 2022 - 8 February 2022

Pharmacist Substitution of PBS Medicines without a Prescription during Shortages (Serious Scarcity Substitution Instrument) - 8 February 2022

Stakeholder Consultation Forum: Post-Market Review of Opiate Dependence Treatment Program Medicines - 3 February 2022

Review of the National Medicines Policy – Consultation on the Draft of the National Medicines Policy – Closes Wednesday 16 February 2022 - 2 February 2022

PBS Website Update - 1 February 2022

January 2022

Outcomes of the December 2021 PBAC Intracycle meeting - 28 January 2022

2022 April Price Disclosure Cycle – Indicative Prices - 27 January 2022

National Medicines Policy Review – Publication of Submissions - 21 January 2022

PBAC Public Summary Documents – September 2021 meeting (first time rejections and deferrals) - 14 January 2022

Updated Agenda for the March 2022 PBAC meeting - 6 January 2022

Consultation Paper on Proposal to Introduce a Cost Recovered Pathway for Medical Services Advisory Committee (MSAC) Applications - 4 January 2022

PBS Website Update - 1 January 2022

2021

December 2021

PBAC Public Summary Documents – September 2021 meeting - 24 December 2021

PBS Expenditure and Prescriptions Report 2020-21 - 24 December 2021

Report on the Collection of Under Co-payment Data 2020-21 - 24 December 2021

Extension to Image Based Prescription Special Arrangement - 22 December 2021

Recommendations made by the PBAC - November 2021 - 17 December 2021

Price Disclosure 2022 April Cycle Outcomes Summary - 10 December 2021

Biosimilar follitropin alfa on the PBS - information for health professionals and patients - 7 November 2021

Agenda for the December 2021 PBAC Intracycle meeting - 3 December 2021

PBS Website Update - 1 December 2021

November 2021

Updated 2021 – 22 Cost Recovery Implementation Statement - 30 November 2021

Agenda for the March 2022 PBAC meeting - 24 November 2021

Semaglutide (Wegovy®) Stakeholder Meeting Outcome Statement - 24 November 2021

The Public Summary Documents (first time rejections and deferrals) – July 2021 meeting - 12 November 2021

Progress update: Post-market Review (PMR) of medicines for smoking cessation - 12 November 2021

Pharmaceutical Benefits Scheme Continued Dispensing Arrangements - 5 November 2021

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 5 November 2021

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 5 November 2021

PBS Website Update - 1 November 2021

Section 19A medicines subsidised by the Pharmaceutical Benefits Scheme - 1 November 2021

October 2021

PBAC Public Summary Documents – July 2021 meeting - 29 October 2021

PBS Arrangements for tocilizumab shortage – 1 November 2021 - 29 October 2021

Recommendations made between March 2021 and November 2021 PBAC meetings - 15 October 2021

Outcomes of the September 2021 PBAC Intracycle meeting - 15 October 2021

Updates to the Procedure Guidance for Listing Medicines on the PBS - 15 October 2021

Review of the National Medicines Policy – Call for Submissions Closed - 11 October 2021

PBS Website Update - 1 October 2021

2021 October Cycle – Brand Price Reductions and Savings to Patients  - 1 October 2021

Biosimilar teriparatide on the PBS - information for health professionals and patients - 1 October 2021

September 2021

Public Consultation for the Post-market Review of Opiate Dependence Treatment Program Medicines will close Friday, 1 October 2021 - 27 September 2021

Pharmacist Substitution of PBS Medicines without a Prescription during Shortages (Serious Scarcity Substitution Instrument) - 18 September 2021

1 October 2021 Price Disclosure Confirmed Prices - 13 September 2021

PBAC Public Summary Documents (first time decisions not to recommend, deferrals and other matters) – May 2021 meeting - 10 September 2021

New Strategic Agreements with the Medicines Industry - 7 September 2021

Updated Agenda for the November 2021 PBAC meeting - 2 September 2021

PBS Website Update - 1 September 2021

August 2021

Review of the National Medicines Policy (NMP) – Call for Submissions – Close Friday 8 October 2021 - 30 August 2021

PBAC Public Summary Documents – May 2021 meeting - 27 August 2021

Recommendations made by the PBAC - July 2021 - 20 August 2021

Pharmacist Substitution of PBS Medicines without a Prescription during Shortages (Serious Scarcity Substitution Instrument) - 20 August 2021

Final Terms of Reference and Public Consultation to the Post-market Review of Opiate Dependence Treatment Program Medicines - 17 August 2021

Pharmacist Substitution of PBS Medicines without a Prescription during Shortages (Serious Scarcity Substitution Instrument) - 16 August 2021

PBS Arrangements for tocilizumab shortage - 13 August 2021

Updated Financial Estimates workbook - 6 August 2021

National Medicines Policy Review Committee and Terms of Reference - 3 August 2021

PBS Website Update - 1 August 2021

July 2021

Announcement of the National Medicines Policy Review Committee and Terms of Reference - 30 July 2021

2021 October Price Disclosure Cycle – Indicative Prices - 30 July 2021

Agenda for the November 2021 PBAC meeting - 28 July 2021

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 21 July 2021

PBAC Public Summary Documents (first time rejections and deferrals) – March 2021 meeting - 16 July 2021

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 13 July 2021

Grant to support residential aged care facilities to upgrade to an electronic National Residential Medication Chart - 9 July 2021

Health Products Portal (HPP) – Outcomes from the Federal Budget 2021-22 - 6 July 2021

PBAC Public Summary Documents for risdiplam – March 2021 meeting - 5 July 2021

PBAC Public Summary Documents – March 2021 meeting - 1 July 2021

Bevacizumab on the PBS - 2 July 2021

PBS Website Update - 1 July 2021

June 2021

Changes to cost recovery arrangements from 1 July 2021 - 25 June 2021

National Medicines Policy Review to begin in August 2021 - 24 June 2021

Price Disclosure 2021 October Cycle Outcomes Summary - 23 June 2021

Outcomes of the May 2021 PBAC Intracycle meeting - 18 June 2021

Efficient Funding of Chemotherapy review – Discussion Paper Submissions Close 2 July 2021- 18 June 2021

Updated Financial Estimates workbook - 10 June 2021

Post-market Review of medicines for smoking cessation – Public Consultation on the Draft Report - 7 June 2021

PBS Website Update - 1 June 2021

May 2021

Post-market Review of Opiate Dependence Treatment Program (ODTP) Medicines - 28 May 2021

New listings for opioid medications on the Palliative Care Schedule for the management of severe disabling pain from 1 June 2021- 21 May 2021

Biosimilar bevacizumab on the PBS - information for health professionals and patients - 21 May 2021

Updated Agenda for the July 2021 PBAC meeting - 7 May 2021

PBS Website Update - 1 May 2021

Cancer expert to head review into efficient and equitable access to chemotherapy medicines -  1 May 2021

April 2021

PBS Website Survey - 29 April 2021

PBAC Public Summary Documents (rejections/deferrals/other matters) - December 2020 Intracycle meeting - 23 April 2021

Recommendations made by the PBAC - March 2021 - 23 April 2021

PBS Website Medicine data update - 20 April 2021

Public Consultation – Draft 2021-22 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 15 April 2021

PBAC Public Summary Documents - December 2020 Intracycle meeting - 9 April 2021

Biosimilar adalimumab on the PBS - information for health professionals and patients - 1 April 2021

PBS Website Update - 1 April 2021

March 2021

Stage 2 PBS Process Improvements – Resubmission Pathways Webinar Recording Available - 31 March 2021

2021 April Cycle - Brand Price Reductions and Savings to Patients - 31 March 2021

Agenda for the July 2021 PBAC meeting - 31 March 2021

Adalimumab Pharmaceutical Benefits Scheme changes - 1 April 2021 - 26 March 2021

Post-Market Review of medicines available on the PBS Opiate Dependence Treatment Program - 24 March 2021

PBAC Public Summary Documents (first time rejections and deferrals) - November 2020 meeting - 19 March 2021

Consultation: Critical Technologies for Australia – Agriculture & Health Sectors - 19 March 2021

1 April 2021 Price Disclosure Confirmed Prices - 18 March 2021

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 18 March 2021

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 18 March 2021

Stage 2 PBS Process Improvements – Resubmission Pathways Webinar - 10 March 2021

PBAC Public Summary Documents - November 2020 meeting - 5 March 2021

PBS Website Update - 1 March 2021

February 2021

Post-market Review of Medicines for Smoking Cessation – Stakeholder Forum outcome - 15 February 2021

Amendments to the process for reviewing and remaking positive PBAC listing recommendations that have not been accepted by applicants - 15 February 2021

Amendment of descriptions and PBS item codes for various PBS listed insulins - 1 February

PBS Website Update - 1 February 2021

January 2021

Recommendations made by the PBAC - December 2020 Intracycle meeting - 29 January 2021

2021 April Price Disclosure Cycle – Indicative Prices - 20 January 2021

PBAC Public Summary Documents (rejections/deferrals/other matters) - September 2020 Intracycle meeting - 15 January 2021

PBS Website Update - 1 January 2021

2020

December 2020

PBAC Public Summary Documents - September 2020 Intracycle meeting - 24 December 2020

Agenda for the March 2021 PBAC meeting - 23 December 2020

Price Disclosure 2021 April Cycle Outcomes Summary - 21 December 2020

PBS Website updates for Stage 2 PBS process improvements - 21 December 2020

Closure of the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis - 21 December 2020

Recommendations made by the PBAC - November 2020 - 18 December 2020

Report on the Collection of Under Co-payment Data 2019-20 - 18 December 2020

PBS Expenditure and Prescriptions Report 2019-20 - 17 December 2020

PBS Website Update - 1 December 2020

November 2020

Stage 2 PBS Process Improvements and revised cost recovery arrangements - Information Forum - 23 November 2020

PBAC Public Summary Documents - July 2020 meeting - 13 November 2020

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 13 November 2020

Post-market Review of Medicines for Smoking Cessation – Targeted Stakeholder Forum - 9 November 2020

PBS Website Update - 1 November 2020

October 2020

Public Summary Documents - PBAC July 2020 - 30 October 2020

Recommendations made by the PBAC - September 2020 Intracycle Meeting and out-of-session between July 2020 and September 2020 Meetings - 16 October 2020

Stage 2 PBS Process Improvements – Consultation Closed - 13 October 2020

Implementation of Stage 2 PBS Process Improvements from 1 January 2021 - 7 October 2020

1 October 2020 Price Disclosure Confirmed Prices - 6 October 2020

PBS Website Update - 1 October 2020

Extension to Image Based Prescription Special Arrangement - 1 October 2020

New Dual Therapy PBS Restrictions for Pulmonary Arterial Hypertension (PAH) Medicines - 1 October 2020

Updated Financial Estimates workbook - 1 October 2020

September 2020

Pharmaceutical Benefits Scheme Continued Dispensing Arrangements - 25 September 2020

Stage 2 PBS Process Improvement Information Forum – Webinar recording and resources available - 24 September 2020

Revised opioids PBS listings from 1 October 2020 - 21 September 2020

PBS Process Improvements – Stage 2 Fact Sheet - 21 September 2020

Simplified Chemotherapy Prescribing Arrangements - 16 September 2020

Stage 2 PBS Process Improvements and revised cost recovery arrangements - Information Forum - 11 September 2020

Biosimilar pegfilgrastim on the PBS - information for health professionals and patients - 11 September 2020

Active Ingredient Prescribing - 10 September 2020

PBS Website Update - 1 September 2020

August 2020

PBAC Public Summary Documents - May 2020 Intracycle meeting - 28 August 2020

Agenda for the November 2020 PBAC meeting - 26 August 2020

Recommendations made by the PBAC - July 2020 - 21 August 2020

Simplified prescribing arrangements for chemotherapy patients during the COVID-19 pandemic - 21 August 2020

PBS Website Update - 1 August 2020

July 2020

Biosimilar insulin glargine on the PBS - information for health professionals and patients - 27 July 2020

2020 October Price Disclosure Cycle – Indicative Prices - 27 July 2020

Pharmacy Trial Program Implementation Review - 24 July 2020

PBAC Statement of Endorsement for transparency measures and standardised redactions to Public Summary Documents - 23 July 2020

PBAC Public Summary Documents (first time rejections and deferrals) - March 2020 meeting - 17 July 2020

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 10 July 2020

PBAC Public Summary Documents - March 2020 meeting - 3 July 2020

PBS Website Update - 1 July 2020

Changes to PBS Online Claiming for Residential Aged Care Claims - 1 July 2020

Expansion of Continued Dispensing Arrangements – COVID-19 - 1 July 2020

June 2020

Price Disclosure 2020 October Cycle Outcomes Summary - 25 June 2020

Seventh Community Pharmacy Agreement (7CPA) - 23 June 2020

Recommendations made by the PBAC - May 2020 Intracycle Meeting - 19 June 2020

Updated PBS Cost Recovery arrangements for 2020-21 - 19 June 2020

Summary of PBS opioid listings for the treatment of pain as of 1 June 2020 - 2 June 2020

Pharmacist claiming of tramadol 50mg capsule prescriptions from 1 June 2020 - 1 June 2020

Pharmacist claiming of paracetamol 500mg + codeine 30mg tablet prescriptions from 1 June - 1 June 2020

PBS Website Update - 1 June 2020

May 2020

New biosimilar trastuzumab on the PBS - information for health professionals and patients - 26 May 2020

Final Report for the post-market review of pulmonary arterial hypertension (PAH) medicines - 25 May 2020

Public Consultation - Draft 2020-21 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 20 May 2020

Serious Shortages Substitution Notice (SSSN) - 14 May 2020

Pharmaceutical Benefits Scheme restriction requirement exemptions for some medicines during the COVID 19 pandemic - 1 May 2020

Revised PBS Restrictions for Pulmonary Arterial Hypertension (PAH) Medicines - 1 May 2020

Revised opioids PBS listings from 1 June 2020 - 1 May 2020

PBS Website Update - 1 May 2020

April 2020

Updates to Antibiotic repeats on the Pharmaceutical Benefits Scheme (PBS) item - PBAC August 2019 - 30 April 2020

Procedure Guidance for standardised redactions to Public Summary Documents is available - 30 April 2020

Agenda for the July 2020 PBAC meeting - 29 April 2020

Updated Financial Estimates workbook - 28 April 2020

Cost Recovery - Consultation Feedback - 28 April 2020

Recommendations made by the PBAC - March 2020 - 24 April 2020

Revised PBS listings for Antibiotic use from 1 May 2020 - 23 April 2020

Revised hydroxychloroquine PBS listings for the treatment of autoimmune disorders and malaria from 1 May 2020 - 23 April 2020

PBAC Public Summary Documents - December 2019 Intracycle meeting - 9 April 2020

Authorised Nurse Practitioners now eligible to prescribe certain Highly Specialised Drugs - 1 April 2020

PBS Website Update - 1 April 2020

March 2020

Expansion of Pharmaceutical Benefits Scheme Continued Dispensing Arrangements Covid-19 - 31 March 2020

1 April 2020 Price Disclosure Confirmed Prices - 31 March 2020

Updated Financial Estimates workbook and manual - 30 March 2020

Biosimilar pegfilgrastim on the PBS - information for health professionals and patients - 24 March 2020

Revised PBS listings for Antibiotic use from 1 April 2020 - 20 March 2020

PBAC Public Summary Documents - November 2019 Meeting (first time rejections and deferrals) - 20 March 2020

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 18 March 2020

Final Terms of Reference and Public consultation to the post-market review of medicines for smoking cessation - 13 March 2020

PBAC Public Summary Documents - November 2019 meeting - 6 March 2020

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents – 6 March 2020

Standardised redactions to Public Summary Documents – nominations open for participation in the final trial, and implementation from July 2020 - 5 March 2020

PBS Website Update - 1 March 2020

February 2020

PBS Cost Recovery Information Forum – Webinar Recording and Resources Available - 17 February 2020

Recommendations made by the PBAC – December 2019 Intracycle Meeting - 13 February 2020

PBS Process Improvements Webinar Information Forum - 3 February 2020

Launch of the Medicine Status Website - 3 February 2020

2020 April Price Disclosure Cycle - Indicative Prices - 3 February 2020

PBS Website Update - 1 February 2020

Biosimilar rituximab on the PBS - information for health professionals and patients - 1 February 2020

January 2020

PBAC Public Summary Documents - August 2019 Intracycle meeting - 31 January 2020

Update of the frequently asked questions for the PBS Botulinum Toxin Program - 23 January 2020

Affordable access to medicines for bushfire affected Australians - 13 January 2020

Biosimilar trastuzumab and rituximab on the PBS - information for health professionals and patients – 2 January 2020

PBS Safety Net threshold lowered – 1 January 2020

PBS Website Update – 1 January 2020

2019

December 2019

Agenda for the March 2020 PBAC meeting - 24 December 2019

Recommendations made by the PBAC - November 2019 - 20 December 2019

Price Disclosure 2020 April Cycle Outcomes Summary - 18 December 2019

PBS Growth Hormone Program (Adult Use) 1 January 2020 Listing Changes - 18 December 2019

Report on the Collection of Under Co-Payment Data 2018-19 - 17 December 2019

PBAC Public Summary Documents - August 2019 Intracycle meeting - 13 December 2019

PBS Expenditure and Prescriptions Report 2018-19  - 13 December 2019

2019-20 Cost Recovery Implementation Statement (CRIS) for PBS/NIP updated for 2018-19 financial outcome - 12 December 2019

Information on Efficient Funding of Chemotherapy reviewed - 5 December 2019

Biosimilar trastuzumab on the PBS - information for health professionals and patients - 2 December 2019

PBS Website Update - 1 December 2019

November 2019

PBAC Public Summary Documents - August 2019 Intracycle meeting - 29 November 2019

Revised risperidone PBS listings for behavioural and psychological symptoms of dementia from 1 January 2020 - 29 November 2019

PBS Process Improvements Information Forum – Webinar Recording and Resources Available - 26 November 2019

Take Home Naloxone Pilot to launch 1 December 2019 - 25 November 2019

TECHNICAL ISSUES UPDATE: PBS Process Improvements Webinar - 21 November 2019

PBAC Public Summary Documents (first time rejections and deferrals) - July 2019 meeting - 15 November 2019

Biosimilar rituximab and insulin glargine on the PBS and other PBS Listing changes - information for health professionals and patients - 14 November 2019

Health Products Portal – Intent to Apply - 14 November 2019

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 13 November 2019

Advice for approved pharmacists supplying PBS medicines to patients in areas affected by Queensland, Victoria, South Australia and NSW Bushfires – 12 November 2019

PBS Process Improvements Information Forum - 7 November 2019

PBS Process Improvements Information Forum – Webinar Recording and Resources Available - 7 November 2019

PBAC Public Summary Documents - July 2019 Meeting - 1 November 2019

PBAC Public Summary Documents - May 2019 meeting - 1 November 2019

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 1 November 2019

PBS Website Update - 1 November 2019

October 2019

PBS statement

Complete: Harmonisation of Authority Required (Streamlined) listings across public and private hospital PBS items for the Section 100 - Highly Specialised Drugs program - 25 October 2019

Post-market review of medicines for smoking cessation - 24 October 2019

PBS Process Improvements Webinar Information Forum - 14 October 2019

Changes to mesalazine from 1 October 2019 - 4 October 2019

Recommendations made by the PBAC - August 2019 Intracycle Meeting - 4 October 2019

Update of PBS forms and procedure guidance for listing medicines on the PBS updated - 3 October 2019

PBS Website Update - 1 October 2019

September 2019

1 October 2019 Price Disclosure Confirmed Prices - 30 September 2019

Health Products Portal - Webinars - 26 September 2019

Electronic Prescribing - 19 September 2019

PBS Website Update - 1 September 2019

August 2019

Harmonisation of Authority Required (Streamlined) listings across public and private hospital PBS items for the Section 100 - Highly Specialised Drugs program - 30 August 2019

Agenda for the November 2019 PBAC meeting - 28 August 2019

Recommendations made by the PBAC - July 2019 - 23 August 2019

Extension to Feedback for Public Consultation - standardised-redactions of public Summary Documents - Open 2 August to 2 September 2019

Biosimilar trastuzumab on the PBS - information for health professionals and patients - 7 August 2019

Public Consultation – Standardised Redactions of Public Summary Documents - 2 August 2019

PBS Website Update - 1 August 2019

July 2019

Application process changes for access to Section 100 - Highly Specialised Drugs (HSD) medicines - 24 July 2019

2019 October Price Disclosure Cycle - Indicative Prices - 22 July 2019

PBAC Public Summary Documents (first time rejections and deferrals) - March 2019 meeting - 19 July 2019

PBS Process Improvements Webinar Information Forum - 18 July 2019

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 17 July 2019

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 12 July 2019

PBAC Public Summary Documents - March 2019 meeting - 5 July 2019

Updated Financial Estimates workbook - 5 July 2019

Changes to wholesale mark-up arrangements for PBS Section 85 medicines dispensed in public and private hospitals to come into effect on 1 October 2019 - 2 July 2019

PBS Website Update - 1 July 2019

June 2019

Recommendations made by the PBAC - May 2019 Intracycle Meeting - 28 June 2019

Agenda for the August 2019 PBAC Intracycle meeting - 27 June 2019

Publication Of Stage 1 PBS Process Improvements - 21 June 2019

Price Disclosure 2019 October Cycle Outcomes Summary - 21 June 2019

Public Consultation – PBS Process Improvements Stage 1 - 19 June 2019

Updated PBAC Calendar and publication of Stage 1 PBS Process Improvements – Procedure Guidance and supporting documents - 17 June 2019

Recommendations made by the PBAC - May 2019 Intracycle Meeting - 14 June 2019

Biosimilar Uptake Drivers - Etanercept - 3 June 2019

PBS Website Update - 1 June 2019

May 2019

Agenda for the July 2019 PBAC meeting - update - 31 May 2019

Recommendations made by the PBAC - March 2019 - update - 31 May 2019

PBS Process Improvements Webinar - Information Forum - 31 May 2019

Asthma Stakeholder Meeting December 2018 – Outcome Statement  - 22 May 2019

PBS Pharmaceuticals in Hospitals Review - 20 May 2019

Health Technology Assessment Consumer Consultative Committee March 2019 Meeting Communiqué - 20 May 2019

PBS Summary of Changes for 1 June 2019 - 10 May 2019

Agenda for the July 2019 PBAC meeting - 1 May 2019

Changes to Proton Pump Inhibitor restriction level - 1 May 2019

PBS Website Update - 1 May 2019

April 2019

Recommendations made by the PBAC - March 2019 - 26 April 2019

PD-L(1) checkpoint inhibitor Stakeholder Meeting Outcome Statement -12 April 2019

Public Consultation – PBS Process Improvements Stage 1 - 10 April 2019

1 April 2019 Price Disclosure Confirmed Prices - 1 April 2019

Correction for Venetoclax restriction - 1 April 2019

Notification regarding restrictions for Nilotinib item 9171Q - nilotinib 200 mg capsule, 120 (Tasigna, NV) - 1 April 2019

PBS Website Update - 1 April 2019

March 2019

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 29 March 2019

Pharmaceutical Benefits Scheme (PBS) Process Improvements Webinar Information Forum - 27 March 2019 

PBAC Report now available - Options for listing PD-(L)1 checkpoint inhibitors for multiple cancer indications on the PBS - 22 March 2019

PBAC Public Summary Documents - November 2018 meeting (rejections and deferrals) - 15 March 2019

Drug utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 15 March 2019

Direct-acting Antivirals for Hepatitis C Outcome Statement - 8 March 2019

Public Consultation – Draft Procedure Guidance and Forms for Listing Medicines on the PBS - 6 March 2019

PBAC Public Summary Documents - November 2018 meeting - 1 March 2019 

PBS Website Update - 1 March 2019

February 2019

Pharmaceutical Benefits Scheme (PBS) Process Improvements Webinar Information Forum - 21 February 2019

Biosimilar Uptake Drivers - 5 February 2019

Public Consultation – Draft Cost Recovery Implementation Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP - 1 February 2019

PBS Growth Hormone Program (Paediatric Use) 1 February 2019 Listing Changes - 1 February 2019

PBS Website Update - 1 February 2019

January 2019

2019 April Price Disclosure Cycle – Indicative Prices - 18 January 2019

Cost Recovery and Pharmaceutical Benefits Scheme (PBS) Process Improvements Information Forums - 14 January 2019

PBS Expenditure and Prescriptions Report 2017-18 - 11 January 2019

Department Update: Implementation of the Improved Payment Administration Arrangements - 2 January 2019

PBS Website Update - 1 January 2019

2018

December 2018

Agenda for the March 2019 PBAC meeting - 19 December 2018

Price Disclosure 2019 April Cycle Outcomes Summary - 14 December 2018

Recommendations made by the PBAC - November 2018 - 14 December 2018

Advice of the amendment to the pricing of eribulin (Halaven®) pharmaceutical items - 10 December 2018

Improved Payment Administration for PBS listed medicines - 7 December 2018

Deferasirox (Jadenau / Exjade) equivalence note - 6 December 2018

PBS Website Update - 1 December 2018

November 2018

Biosimilar Uptake Drivers - 19 November 2018

PBAC Public Summary Documents - July 2018 meeting - 9 November 2018

PBAC Public Summary Documents - April 2018 meeting - 9 November 2018

Report on the Collection of Under Co-payment Data 2017-18 - 5 November 2018

Drug utilisation Sub-Committee (DUSC) Outcome Statement - 2 November 2018

Migalastat (Galafold) included on the Life Saving Drugs Program (LSDP) - 1 November 2018

PBS Website Update - 1 November 2018

October 2018

PBAC Public Summary Documents - July 2018 meeting - 26 October 2018

Drug utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 26 October 2018

New Ministerial Discretion guidance for First New Brand Statutory Price Reductions - 2 October 2018

PBS Website Update - 1 October 2018

September 2018

August 2018 PBAC special meeting - brief outcome now available - 28 September 2018

Recommendations made by the PBAC – August 2018 - 28 September 2018

Revised Ezetimibe & Ezetimibe-Statin Restrictions effective 1 October 2018 - 28 September 2018

1 October 2018 Price Disclosure Confirmed Prices - 27 September 2018

Information Forums - Streamlining Pharmaceutical Benefits Scheme (PBS) Medicines Listing Processes - 18 September 2018

Changes to TGA/PBAC parallel processing arrangements for biosimilar medicines - 18 September 2018

Biosimilar Uptake Drivers - 14 September 2018

Patient Charges for PBS Prescriptions: Example Calculations - 4 September 2018

Biosimilar Awareness Initiative – Literature Review - 3 September 2018

PBS Website Update - 1 September 2018

August 2018

Multiple Myeloma Meeting Outcome Statement - 24 August 2018

Agenda for the November 2018 PBAC meeting - 22 August 2018

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 22 August 2018

Recommendations made by the PBAC – July 2018 - 17 August 2018

Post-market Review of the use of biologics in the treatment of severe chronic plaque psoriasis - 17 August 2018

August 2018 PBAC special meeting – Public submissions now available - 10 August 2018

PBS Schedule – correction 1 August 2018 - 6 August 2018

PBS Website Update - 1 August 2018

PBS Listing of Ezetimibe brands for 1 August 2018

July 2018

2018 October Price Disclosure Cycle - Indicative Prices - 16 July 2018

Biosimilar Uptake Drivers - 16 July 2018

Drug Utilisation Sub Committee (DUSC) Outcome Statement - 13 July 2018

PBAC Public Summary Documents - March 2018 meeting - 13 July 2018 

Cost Recovery Implementation Statement (2018-2019) - 5 July 2018

PBS and NIP Cost recovery - annual indexation of fees - 1 July 2018

PBS Website Update - 1 July 2018

June 2018

PBAC Public Summary Documents - March 2018 meeting

Price Disclosure 2018 October Cycle Outcomes Summary - 21 June 2018

PBS Legislative Amendments – 1 June 2018

Recommendations made by the PBAC - April 2018 - 1 June 2018

PBS Website Update - 1 June 2018

May 2018

August 2018 PBAC special meeting - Invitation for submissions open and background paper available - PD-1 and PD‑L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types - 21 May 2018

Draft report for the post-market review of Pulmonary Arterial Hypertension (PAH) medicines - 21 May 2018

Changes to PBS payment arrangements for certain medicines - 3 May 2018

PBS Website Update - 1 May 2018

April 2018

Agenda for the July 2018 PBAC Meeting - 27 April 2018

PBAC Public Summary Documents – December 2017 - 27 April 2018

Biosimilar Education Grant - 23 April 2018

Recommendations made by the PBAC - March 2018 - 20 April 2018

New Anniversary Price Reductions and Ministerial Discretion guidance material available - 20 April 2018

PBAC Public Summary Documents – December 2017 - 13 April 2018

Reminder – Chemotherapy Compounder ID mandatory within PBS claims -12 April 2018

PBS Website Update - 1 April 2018

March 2018

PBS Legislative Amendments - 26 March 2018

1 April 2018 Price Disclosure Confirmed Prices - 20 March 2018

PBAC Public Summary Documents - November 2017 meeting - 16 March 2018

Drug Utilisation Sub Committee (DUSC) Outcome Statement - 16 March 2018

PBS Price Disclosure – 42 Month Clock list (for a 30% Unadjusted Price Reduction) for the 2018 April Cycle

Update to the April 2018 Price Disclosure Outcomes

PBAC Public Summary Documents - November 2017 meeting - 2 March 2018

Drug Utilisation Sub Committee (DUSC) Utilisation Analysis Public Release Documents - 2 March 2018

PBS Website Update - 1 March 2018

February 2018

Nusinersen Stakeholder Meeting Outcome Statement - 23 February 2018

National Health Amendment (Pharmaceutical Benefits – Budget and Other Measures) Act 2018 - 23 February 2018

August 2018 PBAC special meeting - 19 February 2018

Recommendations made by the PBAC - December 2017

Biosimilar Awareness Initiative - Literature Review - 2 February 2018

PBS Website Update - 1 February 2018

January 2018

Post-market Review of Chronic Obstructive Pulmonary Disease (COPD) Medicines – Final report released - 30 January 2018

Indicative 1 April 2018 Prices - 2018 April Cycle - 30 January 2018

Review of the Life Saving Drugs Program (LSDP) - Final report released - 28 January 2018

Draft report for the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis - 18 January 2018

Price Disclosure 2018 April Cycle Outcomes Summary - 12 January 2018

PBS Website Update - 1 January 2018

2017

December 2017

PBS Expenditure and Prescriptions Report 2016-17 - 20 December 2017

Agenda for the March 2018 PBAC meeting - 20 December 2017

Post-Market Review of Ezetimibe - Final Report - 20 December 2017

Recommendations made by the PBAC - November 2017 - 15 December 2017

Report on the Collection of Under Co-payment Data 2016-17 - 14 December 2017

Amendment to Recommendations made by the PBAC - August 2017 - 13 December 2017

Consumer Outcome Statement for the Post-market Review of PAH Medicines - 8 December 2017

Post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis - Stakeholder Forum outcome - 8 December 2017

Biosimilar Awareness Initiative - Literature Review - 7 December 2017

International Harmonisation of Ingredient Names – PBS changes – Update - 6 December 2017

PBAC Public Summary Documents - August 2017 meeting - 1 December 2017

Biosimilar Uptake Drivers - 1 December 2017

Which biosimilar medicines are available in Australia? - 1 December 2017

PBS Website Update - 1 December 2017

November 2017

Chemotherapy Compounder ID mandatory within PBS claims from 1 December 2017 - 22 November 2017

Drug Utilisation Sub-Committee (DUSC) Outcome Statement for the September 2017 meeting - 10 November 2017

PBAC Public Summary Documents - July 2017 meeting - 10 November 2017

Recommendations made by the PBAC - August 2017 meeting - 3 November 2017

PBS Website Update - 1 November 2017

October 2017

PBAC Public Summary Documents - July 2017 meeting - 27 October 2017

DUSC Utilisation Analysis Public Release Documents - June 2017 meeting - 27 October 2017

Agenda for the December 2017 PBAC meeting - 4 October 2017

PBS Website Update - 1 October 2017

September 2017

Recommendations made by the PBAC - August 2017 - 29 September 2017

TGA and PBAC parallel process now available for vaccines - 26 September 2017

Cost Recovery Implementation Statement (2017-2018) - 26 September 2017

New Fact Sheets - Infliximab biosimilars - 22 September 2017

Confirmed 1 October 2017 Prices - 2017 October Cycle - 14 September 2017

Introduction of mandatory arrangements for Pharmaceutical Benefits Scheme (PBS) Efficient Funding of Chemotherapy (EFC) claims - 5 September 2017

PBS Website Update - 1 September 2017

August 2017

Agenda for the November 2017 PBAC meeting - 23 August 2017

Recommendations made by the PBAC - July 2017 meeting - 18 August 2017

New Appointments to the Pharmaceutical Benefits Advisory Committee - 7 August 2017

Advice about a-flag data 1 August 2017 - 1 August 2017

PBS Website Update - 1 August 2017

July 2017

Post-Market Review of Pulmonary Arterial Hypertension Medicines – Public Consultation Process - 26 July 2017

Post-market Review of the use of biologics in the treatment of severe chronic plaque psoriasis - Stakeholder Forum - 25 July 2017

Additional PBAC Public Summary Documents - March 2017 meeting - 14 July 2017

Indicative 1 October 2017 Prices - 2017 October Cycle - 13 July 2017

New Appointment to the PBAC - 13 July 2017

Drug Utilisation Sub Committee (DUSC) Outcome Statement - 12 July 2017

Pharmacy Review - An Update from the Chair - 12 July 2017

PBS Website Update - 1 July 2017

June 2017

PBAC Public Summary Documents - March 2017 meeting - 30 June 2017

Drug Utilisation Sub Committee (DUSC) Utilisation Analysis Public Release Documents - 30 June 2017

Revised Dispensing for nursing home residents - 30 June 2017

Release of the Review's Interim Report - 22 June 2017

Price Disclosure 2017 October Cycle Outcomes Summary - 16 June 2017

Post-Market Review of the Use of Biologics in the Treatment of Severe Chronic Plaque Psoriasis – Public Consultation Process - 9 June 2017

Transitional arrangements for General Schedule deletions and replacements - 1 June 2017 PBS Schedule - 6 June 2017

Recommendations made by the PBAC - April 2017 - 2 June 2017

New Appointments to the PBAC - 1 June 2017

Netupitant with palonosetron (Akynzeo®) for nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy - 1 June 2017

PBS Website Update - 1 June 2017

May 2017

Draft Report for the Post-market Review of COPD Medicines - 29 May 2017

Post-market Review of Ezetimibe – Revised Draft Report Public Consultation - 23 May 2017

Post-market Review of Ezetimibe – Revised Draft Report - Notice of Public Consultation - 19 May 2017

International Harmonisation of Ingredient Names – PBS changes - 3 May 2017

PBS Website Update - 1 May 2017

April 2017

Agenda for the July 2017 PBAC meeting - 26 April 2017

Recommendations made by the PBAC - March 2017 - 21 April 2017

Drugs and manners of administration that meet the F2/multi-brand criteria (30 month clock for originator removal calculation) for the 2017 October Cycle - 7 April 2017

Report on the Collection of Under Co-payment Data 2015-16 - 5 April 2017

Advice for approved pharmacists supplying PBS medicines to patients in areas affected by Ex-Tropical Cyclone Debbie and subsequent flooding – March 2017 - Updated 4 April 2017 - 5 April 2017

Ex-Tropical Cyclone Debbie - Updated Advice for Pharmacists - 3 April 2017

Biosimilar Awareness Initiative update - 1 April 2017

PBS Website Update - 1 April 2017

March 2017

Advice for approved pharmacists supplying PBS medicines to patients in areas affected by Ex-Tropical Cyclone Debbie – March 2017 - 30 March 2017

National Health Amendment (Pharmaceutical Benefits) Act 2017 - 29 March 2017

Post-Market Review of the Use of Biologics in the Treatment of Severe Chronic Plaque Psoriasis – Public Consultation Process - 28 March 2017

Public Summary Document (PSD) for pembrolizumab (NSCLC) - November 2016 PBAC meeting - 23 March 2017

Additional PBAC Public Summary Documents - November 2016 meeting - 17 March 2017

Chemotherapy Compounding Payment Scheme - Extension to the non-mandatory claiming period - 17 March 2017

Drug Utilisation Sub Committee (DUSC) Outcome Statement- February 2017 meeting - 15 March 2017

Access to Medicines Working Group (AMWG) - December 2016 meeting - 15 March 2017

Confirmed 1 April 2017 prices – 2017 April cycle of Price Disclosure - 10 March 2017

Recommendations made by the PBAC - November 2016 - 7 March 2017

Chronic Obstructive Pulmonary Disorder (COPD) Review - Stakeholder Forum: 21 March 2017 - 6 March 2017

PBAC Public Summary Documents - November 2016 meeting - 3 March 2017

Drug Utilisation Sub Committee (DUSC) Utilisation Analysis Public Release Documents - 3 March 2017

PBS Website Update - 1 March 2017

February 2017

PBS Botulinum Toxin Program Changes - 17 February 2017

March 2017 PBS Schedule - 15 February 2017

Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines – Public Consultation - 10 February 2017

Updated PBAC Outcomes for November 2016 - 7 February 2017

PBS Website Update - 1 February 2017

January 2017

Post-market Review of Ezetimibe – Draft Report Public Consultation Now Open - 27 January 2017

Post-market Review of Ezetimibe – Targeted Stakeholder Forum - 27 January 2017

Recommendations made by the PBAC - December 2016 - 27 January 2017

Indicative 1 April 2017 Prices - 2017 April Cycle - 23 January 2017

Generic Medicines Working Group – 1 December 2016 meeting - 19 January 2017

Updated PBAC Outcomes for November 2016 - 9 January 2017

Post-market Review of Ezetimibe – Draft Report Public Consultation - 6 January 2017

Correction to the description of an item on the Repatriation Pharmaceutical Benefits Schedule – 1 January 2017

PBS Website Update - 1 January 2017

2016

December 2016

Agenda for the March 2017 PBAC Meeting - 21 December 2016

Manual of resource items and their associated unit costs - 21 December 2016

A Message from the Panel - Review of Pharmacy Remuneration and Regulation - 19 December 2016

Introduction into Parliament of National Health Amendment (Pharmaceutical Benefits) Bill 2016 - 19 December 2016

Post-market Review of the use of biologics in the treatment of severe chronic plaque psoriasis – Public Consultation - 19 December 2016

Recommendations made by the PBAC - November 2016 - 16 December 2016

PBS Expenditure and Prescriptions 2015-16 - 16 December 2016

Price Disclosure 2017 April Cycle Outcomes Summary - 15 December 2016

Review of Pharmacy Remuneration and Regulation - Pharmacy Financial Survey Update - 7 December 2016

Review of Pharmacy Remuneration and Regulation - Pharmacy Financial Survey - 2 December 2016

PBS Website Update - 1 December 2016

November 2016

Utilisation and cost model workbook - to accompany the PBAC Guidelines - 29 November 2016

Cost Recovery Implementation Statement (2016 – 2017) - 22 November 2016

Update to PBS Pricing Fact sheet on ‘Setting an approved ex manufacturer price for new or extended listings’ - 15 November 2016

Additional PBAC Public Summary Documents - July 2016 meeting - 11 November 2016

Drug Utilisation Sub Committee (DUSC) Outcome Statement - September 2016 meeting - 9 November 2016

PBS Website Update - 1 November 2016

October 2016

Review of Pharmacy Remuneration and Regulation - 31 October 2016

Post-market Review of Ezetimibe – Targeted Stakeholder Forum: 11 November 2016 - 28 October 2016

PBAC Public Summary Documents - July 2016 meeting - 28 October 2016

Drug Utilisation Sub Committee (DUSC) Utilisation Analysis Public Release Documents - 28 October 2016

Drugs and manners of administration that meet the F2/multi-brand criteria (30 month clock for originator removal calculation) for the 2017 April Cycle - 14 October 2016

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 12 October 2016

PBS Website Update - 1 October 2016

September 2016

PBAC Public Summary Documents - August 2016 - 30 September 2016

Recommendations made by the PBAC - August 2016 - 30 September 2016

Biosimilar Awareness Initiative Literature Review and Project Plan - 30 September 2016

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 29 September 2016

Invitation to access the Community Service Obligation (CSO) funding pool and National Diabetes Service Scheme (NDSS) to supply PBS medicines and NDSS products - 29 September 2016

Cheaper medicines from 1 October - 26 September 2016

Review of Pharmacy Remuneration and Regulation - Submissions closing soon - 22 September 2016

Biosimilar Awareness Initiative Reference Group Communique - 18 August 2016 meeting - 20 September 2016

Generic Medicines Working Group (GMWG) Communique - 19 July 2016 meeting - 20 September 2016

Confirmed 1 October 2016 Prices - 2016 October Cycle - 9 September 2016

Access to Medicines Working Group Communiques - 8 September 2016

Australian Statistics on Medicines 2015

Review of Pharmacy Remuneration and Regulation - Live National Webcast - Join the National Conversation on 7 September - 1 September 2016

PBS Website Update - 1 September 2016

August 2016

Review of Pharmacy Remuneration and Regulation - Online Questionnaire - Have your say now! - 25 August 2016

Submissions to the Review of Pharmacy Remuneration and Regulation - 25 August 2016

Agenda for the November 2016 PBAC Meeting - 24 August 2016

Recommendations made by the PBAC - July 2016 - 19 August 2016

Post-market Review of biological Disease Modifying Anti-Rheumatic Drugs to treat Severe Chronic Plaque Psoriasis and of Pulmonary Arterial Hypertension Medicines – Public Consultation

PBS and RPBS Section 85 Date of Processing and Date of Supply Data - 12 August 2016

1 September 2016 Changes to PBS Efficient Funding of Chemotherapy - 11 August 2016

Public Release of Linkable 10% sample of Medicare Benefits Scheme (Medicare) and Pharmaceutical Benefits Scheme (PBS) Data - 11 August 2016

Drug Utilisation Sub Committee (DUSC) Outcome Statement - 10 August 2016

Post-market Reviews of Chronic Obstructive Pulmonary Disease (COPD) medicines and Ezetimibe – Public Consultation - 5 August 2016

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 5 August 2016

Combination Drugs taking Flow-on Price Reductions for 1 October 2016 - 1 August 2016

PBS Website Update - 1 August 2016

July 2016

2016 October Price Disclosure Cycle - Indicative Prices - 28 July 2016

Review of Pharmacy Remuneration and Regulation - Release of Discussion Paper - 27 July 2016

Report on the Collection of Under Co-payment Data 2014-15 - 18 July 2016

Price Disclosure 2016 October Cycle Outcomes Summary - 18 July 2016

Additional PBAC Public Summary Documents - March 2016 meeting - 15 July 2016

Drug Utilisation Sub Committee (DUSC) Utilisation Analysis Public Release Documents - 8 July 2016

PBAC Public Summary Documents, March 2016 meeting - 1 July 2016

PBS Website Update - 1 July 2016

June 2016

Updated Price Disclosure Arrangements Procedural and Operational Guidelines - 29 June 2016

PBS Hospital Medication Charts - 24 June 2016

Removal of blood glucose test strips from the Pharmaceutical Benefits Scheme on 1 July 2016 - 21 June 2016

Notification of Outcomes for the 2016 October Cycle of Price Disclosure - 20 June 2016

Section 100 IVF Program - updated claiming arrangements - 17 June 2016

Biosimilar Awareness Initiative Reference Group Communiqués - 6 June 2016

PBS Palliative Care Schedule - 1 June 2016

PBS Website Update - 1 June 2016

May 2016

PBS Software Developers website redesign - 25 May 2016

Statement from the Panel for the Review of Pharmacy Remuneration and Regulation - 11 May 2016

Pharmaceutical Benefits Advisory Committee Guidelines Review - 6 May 2016

PBS Expenditure and Prescriptions Report 2014-15 - 4 May 2016

Post-market Reviews of Pulmonary Arterial Hypertension medicines and biological Disease Modifying Anti‑Rheumatic Drugs to treat severe chronic plaque psoriasis - 2 May 2016

PBS Website Update - 1 May 2016

Updated treatment algorithm for the treatment of HER2+ metastatic breast cancer - 1 May 2016

April 2016

PBS and RPBS Section 85 Date of Processing and Date of Supply Data - 29 April 2016

Agenda for the July 2016 PBAC Meeting - 28 April 2016

Recommendations made by the PBAC - March 2016 - 22 April 2016

Record of Stakeholder Meeting - Eculizumab (Soliris®) for Atypical Haemolytic Uraemic Syndrome (February 2016) - 22 April 2016

Post-market Reviews of Medicines to treat PAH and bDMARDs to treat Chronic Plaque Psoriasis - 22 April 2016

Generic Medicines Working Group Communique - 21 April 2016

Generic Medicines Working Group Work Plans - 21 April 2016

Price Disclosure - Drugs and manners of administration that meet the F2/multi-branded criteria (30 month clock for originator removal calculation) for the 2016 October Cycle - 12 April 2016

PBAC Guidelines Review - Public Consultation on co-dependent technology chapter - 12 April 2016

PBAC Guidelines Review - Public Consultation on draft revised PBAC Guidelines now closed - 7 April 2016

PBS Website Update - 1 April 2016

March 2016

Review of Pharmacy Remuneration and Regulation - Message from the Chair - 24 March 2016

Changes to the National Diabetes Services Scheme (NDSS) - 22 March 2016

Confirmed 1 April 2016 prices resulting from the 2016 April Cycle of Price Disclosure - 22 March 2016

Drug Utilisation Sub Committee (DUSC) Outcome Statement - 18 March 2016

Additional PBAC Public Summary Documents, November meeting -18 March 2016

Information Session - Recent PBS Statutory Pricing Changes - 11 March 2016

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 11 March 2016

Post-market Reviews of Chronic Obstructive Pulmonary Disease (COPD) medicines and Ezetimibe – Public Consultation - 8 March 2016

PBAC Public Summary Documents, November meeting - 4 March 2016

DUSC public release documents, October 2015 meeting - 4 March 2016

Post-market Reviews of Chronic Obstructive Pulmonary Disease (COPD) medicines and Ezetimibe – Public Consultation - 4 March 2016

New Hepatitis C treatments listed on the PBS

PBS Website Update - 1 March 2016

February 2016

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 24 February 2016

Pharmacy Trial Programme - 23 February 2016

PBAC Public Summary Documents - July 2015 - 19 February 2016

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 19 February 2016

Review of Pharmacy Remuneration and Regulation - 18 February 2016

PBAC Guidelines website design update - 11 February 2016

Information about the new Hepatitis C treatments from 1 March 2016 - 10 February 2016

2016 April Price Disclosure Cycle - Indicative Prices - 3 February 2016

PBS Website Update - 1 February 2016

January 2016

Biosimilar Awareness - updated implementation framework - 29 January 2016

Generic Medicines Working Group Communiques - 27 January 2016

Updated PBAC Outcomes for November 2015 - 7 January 2016

PBAC Public Summary Documents - March 2015 - 6 January 2016

PBS Website Update - 1 January 2016

Expanded PBS Safety Net early supply arrangements apply from 1 January 2016

2016 PBS co-payment and safety net amounts - 1 January 2016

2015

December 2015

Agenda for the March 2016 PBAC meeting - 23 December 2015

Update - Changes to the conditions under which eculizumab may be prescribed on the PBS

F1 5% Statutory Price Reductions on 1 April 2016 - List of Affected Drugs - 18 December 2015

Recommendations made by the PBAC - November 2015 - 18 December 2015

New evidence prompts changes to conditions for the drug eculizumab

Price Disclosure 2016 April Cycle Outcomes Summary - 16 December 2015

Updated PBAC Outcomes for March and July 2015

Errata to the PBS Schedule for 1 December 2015 - 3 December 2015

Biosimilar infliximab on the PBS - information for health professionals and patients - 1 December 2015

PBS Website Update - 1 December 2015

November 2015

Review of Pharmacy Remuneration and Regulation - 25 November 2015

Reference Group for Eculizumab - 25 November 2015

PBAC Public Summary Documents - July 2015 - 13 November 2015

Drug Utilisation Sub Committee (DUSC) Outcome Statement for the October 2015 meeting - 13 November 2015

Pharmaceutical Benefits Advisory Committee Guidelines Review - 4 November 2015

Over-the-counter items recommended for de-listing or amendment from 1 January 2016

PBAC Public Summary Documents - July 2015

Removal of Originator Brand Data from the Price Disclosure Calculation Worked Example - 2 November 2015

Post-market Reviews of COPD Medicines and Ezetimibe - Extension of public consultation on draft Terms of Reference - 2 November 2015

PBS Website Update - 1 November 2015

October 2015

DUSC public release documents, June 2015 meeting - 30 October 2015

Post-market Reviews of Medicines to treat COPD and Ezetimibe - 16 October 2015

Biosimilar awareness - consultation on implementation - 12 October 2015

PBS Website Update - 1 October 2015

September 2015

Response to Consultation Comments - Price Disclosure Originator Brand Removal - 18 September 2015

Confirmed 1 October 2015 prices resulting from the 2015 October Cycle of Price Disclosure - 18 September 2015

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review - 15 September 2015

PBAC Public Summary Documents - March 2015 - 15 September 2015

Post-market Review of Authority Required PBS Listings - 4 September 2015

Update to examples for No Reduction - Low Volume / Low Discount Items - 2 September 2015

Update to Listing Steps - 2 September 2015

Pembrolizumab (Keytruda®) - Information for patients - 1 September 2015

PBS Website Update - 1 September 2015

August 2015

Changes to Growth Hormone and Botulinum Toxin S100 programs - 26 August 2015

Agenda for the November 2015 PBAC meeting - 26 August 2015

Pharmaceutical Benefit Advisory Committee (PBAC) Guidelines Review – Extension of public consultation - 25 August 2015

Update to Listing Requirements for New Brands and New Items - 24 August 2015

Recommendations made by the PBAC July 2015 - 21 August 2015

Biosimilars on the PBS - Fact Sheets - 21 August 2015

Australian Statistics on Medicines 2012, 2013 and 2014 - 19 August 2015

F1 5% Statutory Price Reduction Fact Sheet - 19 August 2015

Pharmaceutical Benefit Advisory Committee (PBAC) Guidelines Review - 17 August 2015

Originator list for PBS medicines on F2 formulary - stakeholder consultation - brand of octreotide added - 12 August 2015

Updated Indicative 1 October 2015 prices resulting from the 2015 October Cycle of Price Disclosure - 11 August 2015

Originator list for PBS medicines on F2 formulary - stakeholder consultation – Closing date for comments extended until Friday 14th August 2015 - 7 August 2015

Fact Sheet - 2015 Price Disclosure Changes - 7 August 2015

Trametinib (Mekinist®) Managed Entry Scheme for listing on the Pharmaceutical Benefits Scheme – information for patients - 6 August 2015

Crizotinib (Xalkori®) Managed Entry Scheme for listing on the Pharmaceutical Benefits Scheme – information for patients - 6 August 2015

PBS Website Update - 1 August 2015

July 2015

PBAC Minutes for the Managed Access Program Framework

Updated Submission Deadlines and PBS Price Change Fact Sheet - 22 July 2015

Indicative 1 October 2015 Prices - 2015 October Cycle - 21 July 2015

Originator list for PBS medicines on F2 formulary - stakeholder consultation - 20 July 2015

PBAC Public Summary Documents - March 2015

Drug Utilisation Sub Committee (DUSC) Outcome Statement for the June 2015 meeting - 17 July 2015

Post-Market Review of PBS Medicines Used to Treat Asthma in Children - 9 July 2015

PBAC Public Summary Documents - March 2015

DUSC Utilisation Analysis Public Release Documents - February 2015

Changes to the requirements for submitting to the PBAC that take effect July 2015 - 1 July 2015

Cost of goods information (PB11b form) at the time of PBAC submission - 1 July 2015

Transitioning of Herceptin Subsidy to the Pharmaceutical Benefits Scheme (PBS) - 1 July 2015

PBS Website Update - 1 July 2015

June 2015

Changes to certain s100 programs - 26 June 2015

PBS Access and Sustainability Package including the 6CPA - Fact Sheets - 26 June 2015

Move to Six PBS Price Change Points - 25 June 2015

Statement by the PBAC - Safety of Biosimilar Medicines - 19 June 2015

Price Disclosure 2015 October Cycle Outcomes Summary - 18 June 2015

PBS and NIP Cost Recovery - annual indexation of fees - 16 June 2015

PBS Website Update - 1 June 2015

PBS Publications - Design changes to PDF documents - 1 June 2015

May 2015

Outcomes for the Diabetes Post-market Review - 29 May 2015

Recommendations made by the PBAC - April 2015 PBAC Special meeting - 27 May 2015

PBS Access and Sustainability Package including the Sixth Community Pharmacy Agreement - 27 May 2015

Post-Market Review of PBS Medicines Used to Treat Asthma in Children - 19 May 2015

Public consultation on LSDP Review Issues Paper closed - 19 May 2015

PBS Website Update - 1 May 2015

April 2015

Public consultation on LSDP Review Issues Paper extended to 18 May 2015

Opioids Roundtable - 29 April 2015

Agenda for the July 2015 PBAC meeting - 29 April 2015

Pharmaceutical Benefits Advisory Committee Guidelines Review - 27 April 2015

Recommendations made by the PBAC - March 2015

PBAC submission to the Senate Inquiry on the availability of new, innovative and specialised cancer drugs in Australia - 15 April 2015

Department of Health submission to the Senate Inquiry on the availability of new, innovative and specialised cancer drugs in Australia

Submissions open for the Life Saving Drugs Programme Post-market Review Issues Paper - 10 April 2015

PBS Website Update - 1 April 2015

March 2015

PBAC Public Summary Documents - November 2014

Tropical Cyclone Nathan - Advice for Pharmacists - 20 March 2015

Drug Utilisation Sub Committee (DUSC) Outcome Statement - 20 March 2015

Post-Market Review Framework - 18 March 2015

PBAC Stakeholder Meeting - Nitisinone for tyrosinaemia type 1 (February 2015)

Confirmed 1 April 2015 prices resulting from 2015 April Cycle of Price Disclosure - 10 March 2015

DUSC Utilisation Analysis Public Release Documents - October 2014

PBAC Public Summary Documents - November 2014

Submissions Published for Review of Authority Required PBS Listings - 4 March 2015

Post-market Review of the Life Saving Drugs Programme (LSDP) - 4 March 2015

PBS Website Update - 1 March 2015

February 2015

Access to Medicines Working Group (AMWG) Communique - December 2014

PBS Website Update - 1 February 2015

January 2015

Indicative 1 April 2015 Prices - 2015 April Cycle - 23 January 2015

Access to Medicines Working Group (AMWG) Communique - 28 October 2014

PBS Website Update - 1 January 2015

2015 PBS co-payment and safety net amounts

2014

December 2014

Agenda for the March 2015 PBAC meeting - 24 December 2014

Recommendations made by the PBAC for the November 2014 meeting - 19 December 2014

PBS Website Update - 1 December 2014

PBS Hospital Medication Charts - Phase One Trials - 1 December 2014

New Conditions of Approval for Approved Pharmacists - 1 December 2014

November 2014

Late-Onset Pompe Disease Stakeholder Meeting - 7 November 2014

PBS Website Update - 1 November 2014

October 2014

Consultation on Draft Type 2 Diabetes Medicines Report - 8 October 2014

PBS Website Update - 1 October 2014

September 2014

Recommendations made by the PBAC for the August 2014 out-of-session meeting - 18 September 2014

Amendments to the Conditions of Approval for Approved Pharmacists - 16 September 2014

AMWG Meeting 7 August 2014 - 10 September 2014

PBS listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome (aHUS) - 9 September 2014

Confirmation of 1 October 2014 Price Disclosure Prices - 4 September 2014

PBS Website Update - 1 September 2014

August 2014

Post-market Review of Authority Required PBS Listings - 29 August 2014

Agenda for the November 2014 PBAC meeting - 27 August 2014

Recommendations made by the PBAC - 22 August 2014

Post-market Review of Authority Required PBS Listings Public Consultation - 13 August 2014

Life Saving Drugs Programme Post-market Review - 11 August 2014

Ivacaftor stakeholder Meeting - 11 August 2014

PBS Website Update - 1 August 2014

July 2014

PBS Hospital Medication Chart - 28 July 2014

Indicative 1 October 2014 prices - Price Disclosure (SPD) - 18 July 2014

PBAC Public Summary Documents - 18 July 2014

Updated Price Disclosure Guidelines and Cycles Table are available - 15 July 2014

Post-Market Review of Products Used for Diabetes Management - 4 July 2014

PBAC Public Summary Documents - 4 July 2014

Access to Medicines Working Group Communique (June 2014) - 1 July 2014

PBS Website Update - 1 July 2014

June 2014

2014 October Cycle Outcomes Summary - 19 June 2014

Simplified Price Disclosure - 6 June 2014

PBS Website Update - 1 June 2014

May 2014

Post-market Review of Authority Required PBS Listings – Public Consultation - 27 May 2014

Post-market Review of Authority Required PBS Listings - 23 May 2014

2014 Budget information on the Pharmaceutical Benefits Scheme - 13 May 2014

Post-market Review of PBS Medicines Used to Treat Asthma in Children Review - 12 May 2014

Diabetes Review Stakeholder Forum summaries & upcoming consultation - 9 May 2014

Errata to the PBS Schedule for 1 May 2014 - 8 May 2014

Stakeholder Forum Outcomes - Asthma Post-market Review - 5 May 2014

PBS Website Update - 1 May 2014

April 2014

Australian Statistics on Medicines 2011 - 17 April 2014

Summary of 1 August 2014 price reductions - 17 April 2014

Tropical Cyclone Ita - 11 April 2014

PBS Website Update - 1 April 2014

March 2014

Confirmation of 1 April 2014 Price Disclosure Prices and New Price Disclosure Fact Sheet - 12 March 2014

Streamlined PBS pricing processes to improve access to medicines - 7 March 2014

PBS Website Update - 1 March 2014

February 2014

PBS Website Update – 1 February 2014

January 2014

PBS Mobile Website - 24 January 2014

WA Bushfire Emergency - temporary PBS arrangements for fire-affected zones - 17 January 2014

PBAC Guidelines website - 16 January 2014

2014 PBS co-payment and safety net amounts - 3 January 2014

PBS Website Update – 1 January 2014

2013

December 2013

Summary of 1 April 2014 price reductions for the 2014 Main Cycle by drug/ manner of administration/ percentage reduction - 16 December 2013

Price Disclosure (Simplified Price Disclosure) - 11 December 2013

PBS Website Update – 1 December 2013

November 2013

Updated Price Disclosure Guidelines - 26 November 2013

Advance notice of 1 December 2013 new prices resulting from 2013 Supplementary Cycle B of EAPD - 4 November 2013

PBS Website Update – 1 November 2013

October 2013

New listings for the PBS announced - 28 October 2013

NSW Bushfire Emergency - temporary PBS arrangements for fire-affected zones - 22 October 2013

Stakeholder Forum: PBS Medicines Used to Treat Asthma in Children - 17 October 2013

PBS Website Update – 1 October 2013

September 2013

Agenda for the November 2013 PBAC meeting - 26 September 2013

PBS Website Update – 1 September 2013

August 2013

Post-Market Review of Products Used for Diabetes Management - 26 August 2013

Stakeholder Forum: Stages 2 and 3 of the Diabetes Post-Market Review - 8 August 2013

PBS Website Update – 1 August 2013

July 2013

New Listings for the PBS Announced – 1 July 2013

PBS Website Update – 1 July 2013

June 2013

Post-Market Review of Medicines Used to Treat Asthma in Children - 17 June 2013

Cost Recovery – Annual Indexation of Fees - 14 June 2013

Amendment for Rosuvastatin – 4 June 2013

PBS Website Update – 1 June 2013

May 2013

Report - Trends in and drivers of Pharmaceutical Benefits Scheme expenditure - 27 May 2013

Call for Submissions: Stage 3 of the Post-Market Review of Products Used in the Management Diabetes - 22 May 2013

PBS Website Update – 1 May 2013

April 2013

PBAC Recommendations from Alzheimers Post-Market Review - 23 April 2013

Reminder - Deadline for Submissions to the August 2013 PBPA meeting - 5 April 2013

PBS Website Update – 1 April 2013

March 2013

Post-Market Review of Products Used for Diabetes Management - 12 March 2013

PBS Website Update – 1 March 2013

February 2013

Subsidy for groundbreaking virus treatments - 19 February 2013

Australian Statistics on Medicines 2010 - 13 February 2013

Post-Market Review of Pharmaceutical Benefits Scheme Medicines to Treat Asthma in Children - 12 February 2013

PBS Website Update – 1 February 2013

January 2013

Agenda for the March 2013 PBAC meeting - 30 January 2013

An alternate brand of Morphine sulfate 10 mg/mL injection is now available on the PBS - 25 January 2013

PBS Website Update - 1 January 2013

2012

December 2012

Post-Market Review of Products Used for Diabetes Management - 20 December 2012

Review of Anticoagulation Therapies in Atrial Fibrillation: Release of Final Report - 18 December 2012

Notes for December 2012 Court Case Errata – docetaxel and risedronate - 12 December 2012

Post-Market Review of Products Used for Diabetes Management - 4 December 2012

PBS Website Update - 1 December 2012

Changes to the December PBS Schedule - 1 December 2012

November 2012

Early release of the December 2012 PBS Schedule - 28 November 2012

2013 PBS Calendar is now available - 21 November 2012

Growth Hormone News Update - Saizen® Solution - 7 November 2012

Report to the PBAC - Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease - 2 November 2012

The PBS Schedule is not changing in November - bigger changes are on the way for December 2012 - 1 November 2012

October 2012

Price changes for the PBS - 24 October 2012

IMPORTANT NEW MEDICINES LISTED ON THE PBS - 24 October 2012

Post-Market Review of Products Used for Diabetes Management - 16 October 2012

PBS Website Update - 1 October 2012

September 2012

Independent Review of the Impact of PBS Cost Recovery -19 September 2012

Report to Parliament – Pharmaceutical Industry Discussion Group (PIDG) - 13 September 2012

PBS Website Update - 1 September 2012

August 2012

2012 Changes to PBS Pricing Arrangements – National Health (Pharmaceutical Benefits) Amendment Regulation 2012 (No. 4) – 24 August 2012

Submissions to the Review of Pharmaceutical Benefits Scheme Listed Anti-dementia Drugs to Treat Alzheimers Disease - 24 August 2012

Growth Hormone News Update - Short Dated Stock - 7 August 2012

Increased prices to consumers for 85 brands of Medicine from 1 August 2012 - 5 August 2012

PBS Website Update - 1 August 2012

July 2012

Review of Anticoagulation Therapies in Atrial Fibrillation: Update - 23 July 2012

Review of Anticoagulation Therapies in Atrial Fibrillation: Reminder - 9 July 2012

1 November 2012 Pharmaceutical Benefits Scheme Schedule - 2 July 2012

PBS Website Update - 1 July 2012

Streamlined Authority Data Capture for all PBS Authority Required (STREAMLINED) drugs - 1 July 2012

June 2012

Review of Anticoagulation Therapies in Atrial Fibrillation: Issues and Options Paper and Stakeholder Forum - 29 June 2012

PBS Calendar - 29 June 2012

New PB11a form - 28 June 2012

Cost recovery – annual indexation of fees - 22 June 2012

2012 Changes to PBS Pricing Arrangements - 1 June 2012

PBS Website Update - 1 June 2012

May 2012

Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease - 28 May 2012

PBS Website Update - 1 May 2012

April 2012

Review of Anticoagulation Therapies in Atrial Fibrillation - 4 April 2012

PBS Website Update - 1 April 2012

March 2012

Revised Arrangements for the Efficient Funding of Chemotherapy Drugs - Full implementation from 1 April 2012 - 29 March 2012

Amendment to the pricing of RPBS items: DRESSING—FOAM with SILICONE—HEAVY EXUDATE - 22 March 2012

Report to Parliament: Pharmaceutical Industry Discussion Group (PIDG) - 13 March 2012

PBS Website Update - 1 March 2012

Changes to brand premiums for 1 April 2012 - Price disclosure reductions for Main, First Transitional and Second Transitional Cycles - 1 March 2012

Information on the availability of pain-killers containing dextropropoxyphene - 1 March 2012

February 2012

Extension to deadline for submissions to Review of Anticoagulation Therapies in Atrial Fibrillation - 21 February 2012

Price increases for 1 April 2012 - 21 February 2012

PBS Website Update - 1 February 2012

January 2012

Agenda for the March 2012 PBAC meeting - 25 January 2012

PBS Website Update - 1 January 2012

2011

December 2011

Call for Submissions: Review of Anticoagulation Therapies in Atrial Fibrillation - 22 December 2011

Summary of 1 April 2012 Price Reductions for Main, First Transitional and Second Transitional Cycles - 19 December 2011

Update on information regarding Price Disclosure Determinations for 1 April 2012 price reductions - 14 December 2011

Amendment to the Efficient Funding of Chemotherapy Schedule effective 1 December 2011

PBS Website Update - 1 December 2011

November 2011

Revised Arrangements for Chemotherapy Drugs & Streamlined Authority Data Capture from 1 December 2011 - 11 November 2011

PBS Website Update - 1 November 2011

October 2011

Important New Medicines Approved for Listing on the PBS - 6 October 2011

PBS Website Update - 1 October 2011

September 2011

Changes to PBS listing deadlines - 30 September 2011

Pharmaceutical Benefits Scheme (PBS) Deferrals Statement of principles of commitment between stakeholders - 30 September 2011

Changes to the Schedule of Pharmaceutical Benefits publication dates - 29 September 2011

Agenda for the November 2011 PBAC meeting - 21 September 2011

Independent Review of the Impact of PBS Cost Recovery - 13 September 2011

PBS Website Update - 1 September 2011

August 2011

Access to Medicines Working Group, May 2011 Meeting - 31 August 2011

Recommendations made by the PBAC (July 2011) - 19 August 2011

Access to Medicines Working Group, December 2010 Meeting - 18 August 2011

PBS Website Update - 1 August 2011

July 2011

Pharmaceutical Benefits Scheme Collection of Under Copayment Data - 21 July 2011

PBS Website Update - 1 July 2011

June 2011

PBS Website Update - 1 June 2011

May 2011

Access to Medicines Working Group, August 2010 Meeting - 20 May 2011

PBS Website Update - 1 May 2011

April 2011

Medicine Brand Choices Campaign - 15 April 2011

PCEHR Concept of Operations Consultation - 14 April 2011

PBS Website Update - 1 April 2011

March 2011

PBS Website Update - 1 March 2011

February 2011

Fact Sheets for Industry - 18 February 2011

Fact Sheet for Be medicinewise is now available - 18 February 2011

Amendment to the pricing of FLUDARABINE PHOSPHATE and EZETIMIBE with SIMVASTATIN - 2 February 2011

Extension of the listing of nicotine patches - 2 February 2011

PBS Website Update - 1 February 2011

January 2011

Agenda for the March 2011 PBAC meeting - 27 January 2011

Addendum to PBS Schedule - 20 January 2011

Water-related infections – advice for Prescribers - 20 January 2011

PBS Website Update - 1 January 2011

2011 PBS copayment and Safety Net amounts - 1 January 2011

Unavailability of Salofalk® 1g moulded suppository - 1 January 2011

 

There is more News available from the Archived News